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Abstract 
 
Despite therapeutic and interventional technological advances, the global burden of 
cardiovascular disease is increasing. Accumulated deoxyribonucleic acid (DNA) damage and 
subsequent repair pathways are now increasingly recognised as a causal factor in the 
initiation and progression of atherosclerosis. These molecular alterations have been shown 
to occur within affected vasculature, plaque microenvironment as well as in circulating cells. 
The DNA damage response (DDR) pathway is reliant on post-translational modification of 
sensing proteins which activate a signalling cascade to repair, if possible, DNA damaged sites 
in response to various environmental and physiological insults.  
Most studies to-date have focussed on animal models and cells cultured directly from 
atherosclerotic plaque to ascertain if altered DDR and DNA repair exist and indeed 
contribute to the atherosclerotic process. By using peripheral whole blood as the base for 
down-stream analyses, an accessible method of determining if altered expression of genes 
involved in DDR and enzymes involved in DNA repair could be exploited. 
DNA ligase is crucial in single (ssDNA) and double-stranded DNA break repair (DSBR) by 
facilitating the joining of DNA strands by catalysing phosphodiester bond formation. It was 
therefore chosen as a marker of DNA repair being a key enzyme involved in base excision 
repair (BER) and DSBR.  
This study examined the differential expression of 22 genes pertinent in the DNA damage 
and response pathway (DDR), in addition to DNA ligase activity, between patients with 
stable, unstable coronary atherosclerosis (both undergoing percutaneous coronary 
intervention for obstructive coronary disease) and healthy controls.  In addition, 
correlations were performed between atherosclerotic plaque features and both DNA ligase 
activity and the genes of interest. To accurately analyse plaque morphology, frequency 
domain optical coherence tomography (FD-OCT) was used which allowed high resolution 
delineation of fibrous tissue, lipid accumulation, calcific deposition and fibrous cap 
thickness, all key features in plaque vulnerability and therefore of clinical significance. 
Peripheral blood mononuclear cells (PBMC) were isolated and DNA repair activity was 
measured from derived nuclear extracts, using a novel microplate assay examining mean 
apparent DNA ligase activity. A custom microarray for the 22 genes of interest was used to 
perform quantitative reverse transcription polymerase chain reaction for differential gene 
expression between all 3 cohorts of patients recruited.  
Data from this study demonstrated differences in DNA ligase activity and expression of 
genes involved in the DDR in patients with coronary atherosclerosis. DNA ligase activity 
correlated with the arc of lipid and cap thickness in both stable and unstable coronary 
patients. Differential DDR gene expression also correlated with fibrous cap thickness, 
predominantly in the unstable coronary group. This suggests that such alterations may 
contribute to the development and progression of the atherosclerotic lipid rich necrotic core 
as well as protective fibrous cap thickness.  
Although significant correlations were found between DNA ligase, genes of interest and 
plaque features, this study demonstrates an association but does not provide a direct 
mechanism by which alterations in DDR contribute to atherogenesis.  
Further studies are required to address differential expression across a broader spectrum of 
genes involved in DDR in coronary artery disease. 
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1.0 INTRODUCTION 
Cardiovascular disease (CVD) remains the leading worldwide cause of death, with a myriad 
of risk factors such as diabetes mellitus, smoking, hypertension, hypercholesterolaemia and 
obesity along with predisposing genes result in a complex multifactorial disease process. It 
accounts for 17.3 million deaths worldwide and is expected to rise to 23.6 million by 2030 
[1]. Coronary artery disease accounts for the greatest proportion of CVD worldwide (see 
figure 1.1) and remains the largest single cause of death in UK.  
 
Figure 1.1: Proportions of cardiovascular deaths worldwide attributed to different 
categories of cardiovascular disease in both males and females in 2011. [2] (Adapted from 
the Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, World Health 
Organization, 2011) 
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The age-standardised incidence and mortality rate from CVD is lower in England compared 
with Scotland, Wales and Northern Ireland, with a more marked difference observed for 
men than for women [3]. CVD associated mortality also appears to be strongly related to 
age and gender, with three times as many men suffering a myocardial infarction compared 
with women [4]. Over the years medical advances in managing CVD have resulted in a 
significant decline in mortality in the UK, however, it remains a significant burden, both in 
terms of health and costs, particularly in secondary care. Widespread adoption of 
antiplatelet, lipid-lowering and anti-hypertensive medications along with continuously 
evolving interventional strategies in the form of percutaneous coronary intervention or 
coronary artery bypass grafting, have revolutionised the modern management of coronary 
artery disease and contributed to the mortality decline.  
More recently, genome-wide association studies have attempted to identify mechanisms 
not completely understood in the atherosclerotic process, such as epigenetic gene 
regulation [5]. In addition to traditional risk factor modulation, further research has been 
undertaken to identify genomic pathways and targets for cardiovascular risk stratification as 
well as reduction [6]. Despite advances in this field, reliable biomarkers of atherosclerotic 
plaque instability remain elusive and merit further analysis. 
 
1.1 Process of atherosclerosis 
The large majority of coronary artery disease results from atherosclerosis, a fibro-
proliferative and inflammatory process resulting in activation of cytokines, growth factors 
and vasoregulatory mechanisms resulting in focal intimal thickening and ultimately luminal 
obstruction [7]. A heterogeneous group of cells are recruited consisting of lymphocytes, 
macrophages, collagen, vascular smooth muscle cells (VSMC), extracellular matrix proteins 
and lipids, with varying degrees of calcification seen within plaques in advanced disease [8].  
Subendothelial retention of apolipoprotein B-containing lipoprotein initiates the 
atherosclerotic process in focal areas of affected arteries, particularly at branch or bend 
points where laminar flow is disturbed [9, 10]. Once these low-density lipoproteins (LDL) 
enter the intimal microenvironment through lipoprotein interactions with other molecules 
such as phospholipase A2, sphingomyelinase and lipoprotein lipase, they become 
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susceptible to pro-atherogenic modifications thereby triggering a low grade inflammatory 
response [10,11]. Once modified, LDL particles induce endothelial chemotactic substance 
secretion and expression of adhesion receptors including integrins and selectins, ultimately 
leading to lymphocyte and monocyte recruitment with subsequent migration into the 
arterial wall. Monocytes preferentially migrate to subendothelial areas with a high density 
of modified LDL particles, after which colony-stimulating factor catalyses the transformation 
of monocytes to macrophages [12]. By expressing scavenger receptors, cholesterol esters 
and oxidised particles are phagocytosed to form foam cells, a key constituent of the 
atherosclerotic plaque [13]. These corrupted macrophage-turned foam cells release a 
myriad of growth factors, cytokines, pro-thrombotic tissue factor and matrix 
metalloproteinases (MMP) which in turn perpetuate inflammation, thereby inducing arterial 
remodelling and plaque vulnerability to acute rupture with subsequent thrombus formation 
[14] (see figure 1.2). 
  
 
 
Figure 1.2:  Adapted from Licastro et al. (2005). Mechanism of atherosclerotic plaque 
formation: Schematic representation of inflammatory mechanisms involved in the 
pathogenesis of atherosclerosis and plaque formation outlining monocytes and 
macrophages as protagonists of process [8]. 
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As the plaque evolves, pro-inflammatory cytokines stimulate VSMC to modify their 
phenotypic behaviour from non-proliferative contractile function in a healthy state, to an 
active proliferative state. This process aids with the migration of VSMC from the vascular 
media to the intima, resulting in increased extracellular matrix synthesis, intimal thickening 
seen in early atherosclerosis and eventual vascular remodelling [15,16]. When outward 
vascular remodelling occurs, it results in the preservation of luminal blood flow and 
beneficial collateral vessel formation helping prevent end organ ischaemia. Hence, acute 
vascular sequelae do not occur from most atherosclerotic lesions [17]. However, this 
expansive or positive remodelling has been considered as a potential surrogate for plaque 
instability [18]. The accumulation of lipid within the plaque is further accelerated by 
isotypes of LDL receptors expressed by VSMC, following migration to the intimal layer [19]. 
Atherosclerotic lesions then undergo a partial resolution process characterised by scarring, 
resulting in a protective fibrous cap which consists of VSMC, proteoglycans, collagen and 
pro-inflammatory macrophage-derived foam cells [20]. This fibrous cap forms a barrier 
between the pro-thrombotic components of a lipid-rich atherosclerotic plaque and 
circulating platelets [21].  
Over time, features of vulnerable plaques can develop which predispose the lesion to 
propagate acute thrombotic vascular disease. Such lesions are formed of a thin fibrous cap 
overlying a large necrotic lipid core and a heightened inflammatory state. In clinical practice, 
these are termed thin-capped fibroatheromas (TCFA), with the fibrous cap quantified as less 
than 65µm overlying a large lipid pool or necrotic core with macrophage activity 
characterising active inflammation. If the thin fibrous cap breaks down, the protective 
barrier is redundant and acute luminal thrombosis with resultant end organ ischaemia 
ensues. Although the hallmark of disease progression is the insidious formation of the 
atherosclerotic plaque, mortality is most commonly associated with acute rupture of these 
vulnerable plaques [22]. The thinning of the fibrous cap is attributed to defective collagen 
synthesis by intimal VSMC and increased MMP degradation secreted by activated 
inflammatory cells [23]. Studies measuring the fibrous cap thickness have shown that the 
incidence of TCFA is highest in acute coronary syndromes, the highest risk manifestation of 
coronary atherosclerosis, and lowest in chronic stable angina [24.25]. Clinical presentations 
of unstable coronary disease, higher risk or acute coronary syndromes are therefore 
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dependent on clinical examination, electrocardiographic, biomarker and myocardial imaging 
tests.  
Clinical examination and subsequent tests therefore aid with categorising the patient along 
the spectrum of acute coronary syndrome; ST segment-elevation myocardial infarction or 
STEMI, (typically acute rupture of a plaque causing acute luminal obstruction), non ST-
segment elevation myocardial infarction or NSTEMI, (typically severe stenosis in one or 
more vessel without acute luminal obstruction or high risk vulnerable plaque features that 
do not result in acute luminal obstruction at the time of presentation, but results in 
biomarker of myocardial necrosis being released into the peripheral blood stream) or 
unstable angina (typically no luminal obstruction but potentially severe stenosis in one or 
more coronary arteries that does not result in myocardial necrosis and subsequent release 
of cardiac biomarkers of necrosis into the peripheral blood stream). 
Despite progress in identifying major inflammatory pathways involved in atherogenesis, the 
molecular mechanisms promoting atherosclerotic plaque components that confer plaque 
instability are not well understood. Over the past two decades, advances in genomic 
research have established a growing body of evidence linking deoxyribonucleic acid (DNA) 
damage to cells within the plaque, as well in the circulation of affected individuals, with 
studies indicating a correlation with disease severity [26.27]. This in turn has fuelled further 
research into understanding DNA repair mechanisms employed to combat genomic 
instability at a cellular level, which can affect vascular function, induce cell cycle arrest, 
apoptosis and premature vascular ageing. Modulation of the DNA damage response 
pathway has been shown to affect atherosclerotic plaque composition in mouse models 
[28], specifically affecting the ratio of fibrous cap to atherosclerotic plaque, but limited data 
exists to examine gene expression and its correlation with human atherosclerotic plaque 
morphology, which may be exploited for potential future therapies to curb plaque 
instability. 
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1.2 Overview of DNA damage and response (DDR) pathway 
Prior to explaining their relevance in atherosclerosis, it would be prudent to review the key 
components currently thought to be involved in the DDR pathway. A comprehensive 
overview of the effects of DNA repair on atherosclerosis would also provide the basis for 
investigating particular repair enzyme activity on plaque constituents, thereby proposing a 
mechanism for modulating plaque morphology conferring potential atherosclerotic plaque 
stability.  
Damage to cellular DNA is induced by multiple exogenous and endogenous factors, resulting 
in mutagenesis and a predisposition to pathologies such as cancer as well as atherosclerosis. 
A complex mechanism of signalling proteins collectively referred to as the DDR, are involved 
in preserving genomic integrity [29]. Salient features include recruitment of DNA repair 
factors to the site of damage after signalling proteins have detected structural alterations in 
base structure and/or pairing, followed by the physical repair of the damaged site [30]. 
Therefore, to prevent the replication and propagation of mutated DNA during the cell cycle, 
specific checkpoint mechanisms are employed integrating DNA repair with cell cycle 
progression [26]. 
A number of DNA repair pathways have been identified including nucleotide excision repair 
(NER) [31], base excision repair (BER) [32], double strand break repair (DSBR) [33] and 
mismatch repair (MMR) [34]. DSBR can be further subdivided into homologous 
recombination (HR), which uses an undamaged sister chromatid as a template for repair, 
and non-homologous end joining (NHEJ), which modifies broken DNA ends and ligates them 
together regardless of homology making it more prone to errors such as base deletions and 
insertions [35]. Despite being more error-prone, NHEJ can operate in any phase of the cell 
cycle, as opposed to HR which is restricted to the post replicative late S and G2 phase. 
Proteins involved in the DDR can be broadly categorised, albeit with a degree of overlap, 
into sensors which first detect damaged DNA, transducers or mediators which initiate a 
signalling cascade to effectors downstream which elicit a specific cellular response such as 
cell cycle arrest, delay, DNA repair or apoptosis if the damage is deemed too severe for 
recovery [36]. 
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1.2.1 Sensor proteins 
As DSBs are lethal and mutagenic lesions, both HR and NHEJ have evolved to mitigate 
against DSB-induced cytotoxicity or gross chromosomal aberrations that can develop. The 
MRN complex is a protein complex crucially involved in the various stages of the DSB 
damage repair response as well as in telomere maintenance. It consists of three proteins, 
namely MRE11, RAD50 and NBS1. MRE11 is a protein composed of two C-terminal DNA-
binding domains along with an N-terminal phosphoesterase domain [37]. It can bind to 
intrinsic DNA, perform endo and some exonuclease activities against both single and 
double-stranded DNA [38], and forms a complex through its phosphoesterase domain with 
NBS1 through its binding sites [39]. RAD50 has structural maintenance properties which 
help to control the dynamics of chromatin. It contains a long internal coil-coil domain that 
brings the N- and C-termini together to form a bipartite ATP-binding cassette-type ATPase 
domain, serving as a dimerization domain through a zinc-binding motif forming a ‘zinc-hook’ 
[40]. MRE11/RAD50 nuclease forms a multimeric complex with the third component, NBS1 
at the C-terminus, and recruits or retains them at sites of DNA damage. It directly binds to 
histone H2AX, which is phosphorylated by the signal transducing ataxia-telangiectasia 
mutated gene product (ATM), in response to DNA damage [41]. This cumulative effect leads 
to an efficient MRN-induced DSB DNA damage signalling response. Mutations in NBS1 
causes Nijmegen breakage syndrome, an autosomal recessive disorder associated with 
chromosomal instability which shares many characteristics associated with the ataxia-
telangiectasia (A-T) syndrome [42].  
Gray et al (2015) used smooth muscle cell-specific NBS1 transgenic mice to demonstrate 
that by modulating the DDR pathway to retard or accelerate DSBR, plaque composition and 
stability could be affected. Despite VSMC DNA damage having little effect on atherogenesis, 
they found it was associated with a reduction in relative fibrous cap area and by 
accelerating DSBR, fibrous cap size and VSMC content was increased. This may indicate that 
DSBR has a role in the atheroprotective effects of stabilising and remodelling a rupture-
prone unstable plaque, although it must be remembered that the study adopted animal 
models to demonstrate the morphological change and cultured SMC may not mimic cell 
activity in-vivo [28]. Additional complementary analyses of DSBR in other major cell types 
within atherosclerotic lesions are needed, but it does suggest the possibility of harnessing 
9 
 
features of ATM kinase, a core protein involved in the DDR, in conferring atherosclerotic 
plaque stability. 
RAD9, RAD1, and Hus1, termed the 9-1-1 complex, is also thought to play an important role 
in the early stages of the DDR. It forms a hetero-trimeric checkpoint-sliding clamp which has 
a similar structure to the proliferating cell nuclear antigen (PCNA) DNA polymerase clamp 
essential in DNA replication [43]. The 9-1-1 complex encircles sites of DNA damage serving 
as a platform for checkpoint and repair protein recruitment to prevent replication until 
repair has occurred. Analogous to PCNA loading onto DNA by the replicating factor C1-5 
(RFC) pentamer, the 9-1-1 complex is attached to DNA damage sites via a RAD17/ RFC 
complex. This triggers ataxia telangiectasia and RAD3-related protein (ATR) mediated 
phosphorylation and activation of downstream DNA damage checkpoint proteins (Chk1 
protein kinase), as well as recruiting DNA polymerase in response to single-stranded DNA 
(ssDNA) damage [44]. 
Another class of sensor proteins that are implicated in various cellular processes including 
ageing, genomic transcription, inflammation, apoptosis, stress response and metabolic 
regulation are sirtuins [45]. Seven isoforms of sirtuins exist in mammals that are 
ubiquitously expressed, with SIRT1, SIRT6 and SIRT7 localised to the nucleus. SIRT3, SIRT4 
and SIRT5 are found in mitochondria and SIRT2 is primarily found in cytoplasm [46]. 
Specifically, sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+) dependent 
lysine deacetylase enzyme which suppresses DNA damage induced apoptosis through 
activation of its substrates including histone proteins, p53, forkhead genes and E2F1 [47]. 
 
1.2.2 Transducer proteins 
ATM and ATR are members of the phosphoinositide 3-kinase related kinase family and form 
the main serine/threonine protein kinases involved in transducing DNA damage signals to 
effectors. Whilst ATM is activated primarily in response to DSB and ATR to ssDNA damage, it 
is now understood that both transducer pathways partially overlap with a more complex 
dynamic than initially thought [48]. 
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ATM deficiency was discovered in A-T syndrome, a rare autosomal recessive disorder 
characterised by genomic instability and a high predisposition to malignancy. Features of 
this condition are due to a lack of the innate ATM-mediated DNA DDR mechanisms and 
include cerebellar impairment, oculomotor apraxia, premature ageing, hypogonadism, 
immunodeficiency and cancer susceptibility [49]. ATM is thought to comprise of a long arm 
and head which wraps around the double-stranded DNA following a conformational change, 
which facilitates affinity for its numerous substrates. It remains inactive in cells without 
DSBs as multimers or dimers, and autophosphorylates on residue Ser1981 post DNA 
damage. This provokes a dissociating cascade of ATM dimers to form active monomers [50]. 
Mediator of DNA damage checkpoint protein 1 (MDC1) binds with MRE11, and the 
stimulation of NBS1 precedes the recruitment of active ATM to sites of DSB, a process that is 
facilitated by the MRN complex [51]. A broad range of substrates are then utilised by ATM 
kinase resulting in a plethora of specific downstream cellular responses including gene 
regulation, translation, maintenance of telomere length and integrity, DNA repair, G1/S, 
intra-S and G2/M checkpoints [52]. In particular, checkpoint protein kinase 2 (Chk2) is 
phosphorylated and activated by ATM in the regulatory cascade resulting in the 
transcriptional activation of tumour suppressor gene p53 [53]. Evidence suggests that ATM 
exerts genomic regulation primarily through HR [54]. 
ATR acts by stabilising replication forks, regulating ssDNA repair and cell cycle progression in 
response to replicative stressors including ultra-violet (UV) light, exposure to toxins such as 
hydroxyurea and hypoxia [52]. ATR interacting protein (ATRIP) aids recruitment of ATR to 
sites of genotoxic-induced DNA damage. In addition to phosphorylating some ATM 
substrates such as p53, it also phosphorylates specific checkpoint proteins Chk1, RAD9 and 
RAD17, as well as the tumour suppressor breast cancer type 1 susceptibility protein 
(BRCA1). ATR is critical in the S and G2 checkpoint phase, and any disruption to this process 
results in replicative mitotic catastrophe. This was shown in mouse models where ATR 
deficiency was associated with death in the early embryonic stage, suggesting its necessary 
function in preventing DNA damage during embryogenesis [55]. In humans, defects in the 
ATR gene causes the autosomal recessive congenital nanosomic disorder, Seckel syndrome, 
characterised by intellectual disability, microcephaly, intra-uterine growth retardation and 
as with Nijmegen breakage syndrome, phenotypic features similar to the A-T syndrome. This 
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reliance on an effective ATR-Chk1 pathway for continual DNA replication has been proposed 
as a potential future target for cancer therapies [56].  
 
1.2.3 Effectors  
Efficient DNA repair is facilitated by the initiation of cell cycle arrest at either the G1/S or 
G2/M phase transitions. Once the damaged DNA has been repaired, normal synthetic 
function is restored after the transient barriers to DNA replication have been removed. 
Checkpoint effector kinases Chk1 and Chk2 are key to this process by phosphorylating 
numerous substrates to regulate the DDR to preserve genetic integrity [57]. Additionally, if 
the degree of DNA damage is so severe that DNA repair cannot be performed, then p53-
activated cellular apoptosis is signalled.  
Chk1 consists of a kinase domain located in the N-terminus, a linker region, a C-terminal 
domain and a regulatory serine/threonine-glutamine (SQ/TQ) cluster domain containing 
multiple phosphorylation sites [58]. Its activation is primarily through phosphorylation by 
ATR forming the ATR-Chk1 pathway mentioned earlier. Chk1 may also be activated via an 
ATR-independent route using mediator proteins such as replication protein A, MDC1, p53-
binding protein 1 (53BP1), topoisomerase-binding-protein 1 (TBP1), Claspin, Timeless and 
Tipin, and RAD17 [59]. Mediators act as substrates and regulators of both transducing and 
effector kinases by promoting their activation as well as controlling their associations with 
damaged DNA. Once Chk1 is activated it induces cell cycle checkpoint arrest by targeting the 
Cdc25 phosphatase family, particularly by inhibiting Cdc25A in the S-phase, and Cdc25C at 
G2/M transition under conditions of genotoxic stress [60]. A cascade of mediator protein 
phosphorylation, sequestration and activation results in the Chk1-dependent activation of 
these intra-S and G2/M checkpoints [61] (see table 1.1). 
Chk2 contains a forkhead-associated protein interaction domain essential for activation in 
response to replication blocks and DNA damage. It is rapidly phosphorylated by ATM on 
T68, a specific threonine residue, located within an N-terminal SQ/TQ-rich motif [62]. When 
this DSB-induced ATM-Chk2 pathway is activated, the encoded protein also inhibits Cdc25C 
phosphatase, preventing entry into mitosis. This has also been shown to stabilize the 
tumour suppressor protein p53 which acts as a transcription factor for p21 leading to cell 
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cycle arrest in G1. Other known substrates of Chk2 include BRCA1 and transcription factors 
such as E2F1and FOXM1 [63-67]. Mutations in the human Chk2 gene results in a 
predisposition to colorectal and breast malignancy [68]. Although originally associated with 
Li-Fraumeni syndrome, a relatively high prevalence of a specific Chk2 mutation in the 
general population has rendered this association unlikely [69]. 
Although the ATM-Chk2 and ATR-Chk1 pathways are evoked in response to DSB and ssDNA 
damage signals respectively, one can see that a highly evolved mechanism exists with a 
great deal of interconnectivity between both pathways as demonstrated in figure 1.3.  
 
 
Figure 1.3: Key proteins involved in the DNA damage response pathway arranged in order of 
sensors, transducers and effectors. A signalling cascade involving all levels of the DDR results 
in a cellular effect of either DNA repair, apoptosis, cell-cycle arrest and/or senescence. 
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Table 1.1:   Summary of the components of the DNA damage response pathway 
CATEGORY NAME SUMMARY OF FUNCTION 
SENSORS 
 
 
MRN (MRE11, RAD50, NBS1) 
 
 
9-1-1 (RAD9, RAD1, Hus1) 
 
 
 
SIRT1 
 
Trimeric complex initiating signalling cascade from 
DSB. Activates transducer ATM mediated pathways. 
 
Heterotrimeric complex serving as an ATR-mediated 
platform for checkpoint and repair protein 
recruitment. 
 
NAD+ dependent lysine deacetylase enzyme 
suppressing DNA damage through its substrate 
activation. 
TRANSDUCERS 
 
 
ATM 
 
 
ATR (& ATRIP) 
Serine/threonine protein kinase transducer activated 
by MRN in response to DSB. 
 
Transducer complex phosphorylates Chk1 in 
response to ssDNA damage from ionizing radiation 
and genotoxic stress. Allows cell cycle arrest and 
DNA repair. 
MEDIATORS 
ATR Signalling 
 
 
 
ATR-independent 
 
 
ATM Signalling 
 
p53BP, MDC1, TPBP1, Claspin, 
Timeless and Tipin 
 
 
RAD17 
 
 
p53BP1, MDC1, BRCA1,  
 
 
ATR-ATRIP recruited to ssDNA damage to 
phosphorylate Chk1 through multiple mediator 
proteins. 
 
Binds to chromatin prior and phosphorylated by ATR 
after DNA damage. G2 checkpoint. 
 
MDC1: Binds with MRE11 facilitating recruitment of 
active ATM to sites of DSB.  
BRCA1: Tumour suppressor gene involved in DNA 
repair +/- apoptosis. 
P53BP1: Checkpoint signalling during mitosis. 
Enhances tumour protein 53-mediated 
transcriptional activation. 
EFFECTORS 
 
Chk1 
 
 
 
Chk2 
G2/M checkpoint activation initiated through ATR-
ChK1 pathway. ssDNA repair, cell cycle arrest and 
apoptosis through downstream signalling.  
 
G1/S and G2/M checkpoints. ATM-Chk2 pathway 
activated in response to DSB. Inhibits Cdc25C, 
stabilises p53 and phosphorylates BRCA1 allowing 
cell cycle arrest apoptosis or DNA repair. 
OTHER 
COMPONENTS 
 
p53 
 
 
Cdc25A 
Cdc25C 
 
Mitosis Promoting Factor (MPF) 
 
p21 
 
γH2AX (Phosphorylated H2AX) 
Tumour suppressor protein. Transducer for G1/S 
checkpoint and p21 transcription. Apoptosis.  
 
Initiation of DNA synthesis. S-phase checkpoint. 
Necessary for G2/M checkpoint. 
 
Necessary for G2/M transition. 
 
CdK4,6 inhibitor. Involved in G1/S checkpoint. 
 
Phosphorylated by ATM and essential in recruiting 
DNA repair proteins via MRN complex formation. 
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1.3 Evidence for DNA damage and repair in atherosclerosis 
Somatic DNA mutations have been implicated in the pathogenesis of atherosclerosis 
resulting from DNA damage ranging from ‘macro’ to ‘micro’ damage [70,71]. Macro damage 
refers to deletions or additions of whole or parts of chromosomes, whereas micro damage 
entails modification of bases (including oxidation), DNA strand breaks, loss of heterozygosity 
(LOH), microsatellite instability (MSI) which involves mutations in regions of DNA that affect 
gene expression, and DNA adducts [36]. As stated earlier, these changes have been 
observed in the plaque environment as well as in the circulation of affected patients [72]. 
It has been proposed that oxidative stress, decreased anti-oxidant level and reduced DNA 
repair efficiency can contribute to progressive atherosclerotic coronary disease [73]. Human 
studies have demonstrated a differential expression of MSI and LOH in atherosclerotic 
lesions compared to normal vascular tissue [74]. Macro-damage in the form of increased 
rates of trisomy 7 and monosomy of chromosome 11 was found in a small study examining 
unstable atherosclerotic plaques [75]. This, along with other chromosomal mutations, has 
demonstrated a propensity to smooth muscle proliferation and the eventual development 
of atherosclerosis [76]. 
Levels of DNA adducts have been shown to correlate with conventional cardiovascular risk 
factors in addition to being an independent predictor of progression of atherosclerotic 
plaques [77,78]. Atherogenic risk factors such as smoking and diabetes in particular have 
been shown to directly cause oxidative DNA damage, inhibition of DNA repair mechanisms 
and acceleration of mutagenic advanced glycation end products [79]. When compared to a 
normal cohort, levels of DNA strand breaks and levels of 8-oxo-guanine, an oxidatively 
modified DNA guanine residue usually formed by reactive oxygen species, are higher in 
patients with atherosclerosis, with some studies also noting a correlation in levels with 
severity of disease [26, 80]. Martinet et al supported this finding by identifying increased 
immunoreactivity to DNA damage markers and up-regulation of DNA repair pathways in 
carotid atherosclerotic plaques [81]. The prevalence of coronary artery disease in ATM 
deficiency is also increased which implies ATM, a key protein in the DNA damage signalling 
cascade, has a role in atherosclerotic progression and genetic inheritance [82,83]. Mercer at 
al. (2010) expanded on this by identifying a correlation between ATM haploinsufficiency, 
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defective DNA repair and a propensity towards increased atherosclerosis and the metabolic 
syndrome [84] 
Reactive oxygen species (ROS) including superoxide anion, hydrogen peroxide and hydroxyl 
radical formation have been linked to oxidative DNA damage resulting in premature ageing 
and progression of atherosclerosis [85, 86]. Subsequent work on mitochondrial dysfunction 
has linked atherogenesis to a combination of increased oxidative intracellular ROS and 
reduced mitochondrial antioxidant pathways, supporting this premise [87]. The 
mitochondrial respiratory chain, nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases, xanthine oxidase, lipoxygenase, uncoupled nitric oxide synthase and 
myeloperoxidase are the primary sources of ROS formation in mammalian cells [88]. To 
counteract the various mechanisms of ROS formation, the role of antioxidant therapy in 
preventing CVD has been examined with little benefit seen from trials examining primary 
and secondary prevention [88-91]. Consequently antioxidant therapy, primarily by vitamin 
supplementation, does not form part of established guidelines for the prevention of CVD. 
Yu et al. (2013) not only concurred with earlier work on ROS inducing mitochondrial DNA 
(mtDNA) damage and its pro-atherogenic effect on the arterial wall [87, 92], but intimated 
that it may be causative rather than just a late consequence of ROS mediated tissue 
damage. They also determined that mtDNA damage was associated with plaque 
vulnerability as determined by assessment of coronary vasculature in stable and unstable 
coronary artery disease with virtual histology intravascular ultrasound [93]. Earlier work by 
Botto et al. (2005) identified a higher incidence of the common mtDNA 4977 base pair 
deletion in patients with atherosclerotic plaques [94], supporting successive studies that 
further demonstrate the correlation between oxidative stress, mtDNA damage and 
atherosclerosis [81,88,93,95]. 
In Apo-E null mice, SIRT1 over-expression was associated with reduced atherosclerosis and 
improved endothelial function [96]. It exerts protection against endothelial dysfunction by 
regulating endothelial nitric oxide and vascular tone through deacetylation of nitric oxide 
synthase [97]. SIRT1 has also been implicated in cholesterol metabolism through 
modulation of nuclear Liver X receptor (LXR), an important transcription factor involved in 
reverse cholesterol transport and atheroprotection. By deacetylating LXR, SIRT1 was shown 
to influence the progression of age-related atherosclerosis [98]. Moreover, there is 
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emerging evidence that SIRT1 regulates the expression of matrix metalloproteinases, 
including the inhibitory tissue metalloproteinase 3 (TIMP3), and by diminishing their 
expression promotes plaque stability [99, 100]. By activating NBS1, a subunit of the MRN 
complex, it additionally promotes DSBR and has been shown to protect against medial 
degeneration and atherosclerosis in VSMC [101] as well as protect the heart against induced 
oxidative stress [102]. 
Telomeres, protective non-coding nucleoprotein structures located at the end of 
chromosomes, progressively shorten with each successive cell replication. They are also 
necessary for genomic stability and evidence has emerged linking telomere shortening with 
diabetes, stable and unstable coronary artery disease [103-105]. In addition to 
environmental and conventional cardiovascular risk factors, it is suggested that shorter 
baseline telomere lengths may predispose to a higher risk of future major adverse 
cardiovascular events [106,107]. Mechanisms to preserve telomere length have been shown 
to reduce atherosclerotic progression including regular aerobic exercise [108], a healthy diet 
[109] and statin therapy [106,110]. 
 
1.4 DNA repair pathways and their effect on atherosclerosis 
Once DNA damage has been detected, repair factors are recruited and physical repair of the 
damaged site ensues. As previously mentioned DSB, NER, BER and MMR are the four main 
DNA damage repair pathways that exist to limit mutagenic replication (as summarised in 
figure 1.4). As some of the major protein pathways involved in DSBR have been discussed 
earlier, this section will focus on the remaining three mechanisms of genomic repair namely, 
NER, BER and MMR.  
NER involves the removal of bulky helix-distorting DNA lesions such as those induced by UV 
light, natural chemical compounds as well as ROS. This process initially involves local 
unwinding of the surrounding DNA using the DNA helicase excision repair cross-
complementing protein 2 (ERCC2) or XPD, which is a component of the TFIIH multi-subunit 
complex. Excision of the damaged DNA by the endonuclease ERCC1 or XPG then follows 
with eventual replacement of the excised DNA using the intact strand as a template [111]. 
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The literature reports various single nucleotide polymorphisms (SNP) associated with 
atherosclerosis [112.113]. The most investigated of these include SNPs occurring within the 
chromosome 9p21.3 locus which has been linked to early coronary artery disease, 
intracranial and aortic/abdominal aneurysm formation from genome wide association 
studies [114.115]. However, a direct mechanistic link between this allele and atherosclerosis 
remains obscure and the risk region is devoid of protein encoding genes. Despite there 
being no association with conventional CVD risk factors, the locus is situated adjacent to a 
cluster of cell cycle regulating tumour suppressor genes, in particular the cyclin-dependent 
kinase inhibitors CDKN2B and CDKN2A. They encode the regulatory proteins p14(ARF), 
p15(INK4b) and p16(INK4a) which are responsible for apoptosis, cell proliferation, 
degeneration and ageing. Analysis of human atherosclerotic plaques have shown an inverse 
relationship between expression of these proteins and VSMC proliferation in the 9p21 
variant, suggesting an important mechanism to explain the association between this genetic 
locus and susceptibility to atherosclerotic CVD [116]. 
In BER, small non-helix distorting base lesions caused by alkylation, oxidation, deamination, 
hydroxylation or methylation produce ssDNA breaks and are removed from the genome. 
The process is initiated by DNA glycosylases such as 8-oxoguanine glycosylase 1 (OGG1) and 
uracil DNA glycosylase (UDG) which recognize and remove the damaged or inappropriate 
bases forming apurinic/apyridiminic (AP) sites. These are then cleaved by AP endonuclease 
with the resulting ssDNA break being repaired by short-patch (single nucleotide repair) or 
long patch BER (up to 10 new nucleotides are synthesized) [117]. Key proteins involved in 
this process include X-ray cross-complementing protein 1 (XRCC1) and poly(ADP ribose) 
polymerase 1 (PARP-1). XRCC1 acts as a scaffold by interacting with repair proteins 
polymerase beta, DNA ligase I (for short patch repair) and DNA ligase III (for long patch) as 
well as signalling/transducing protein PARP at the site of repair.  
To expand on their function, DNA ligase facilitates the joining of DNA strands together by 
catalyzing the formation of a phosphodiester bond. Two covalent phosphodiester bonds are 
formed between 3’-hydroxyl ends of an ‘acceptor’ nucleotide with the 5’-phospate end of 
another ‘donor’ in adjacent DNA residues. This is an adenosine tri-phosphate (ATP) 
dependent mechanism involving the formation of a covalent enzyme adenosine mono- 
phosphate (AMP) intermediate from the cleavage of ATP to AMP and pyrophosphate.  
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The adenylate group from AMP is then transferred to the 5’-phosphate of the nicked DNA 
molecule.  Finally, the DNA ligase seals the gap by phosphodiester bond formation, via the 
displacement of the AMP residue with the 3’-hydroxyl group from the adjacent DNA strand 
[118]. 
ssDNA breaks are repaired using the complementary strand as a template, with DNA ligase 
ensuring complete repair, an ability exploited in DNA repair as well as recombination and 
replication [119]. In addition to DNA ligase I and III in ssDNA damage repair, DNA ligase IV is 
used in DSBR through NHEJ. These ligases have two common domains:  a catalytic domain 
containing several conserved nucleotide-binding motifs, and a conserved non-catalytic 
domain. DNA ligase IV also possesses a long C-terminal extension comprising of two BRCT 
domains, located after the C-terminal domain of the breast cancer susceptibility protein, 
BRCA1. These are phosphopeptide-binding modules found in many proteins that regulate 
DNA damage responses, such as BRCA1, MDC1 and BARD1.  A short linker region that is 
required for the binding of the XRCC4 protein connects the two BRCT domains. A further 
interaction with DNA-dependent protein kinase (DNA-PK) results in the formation of a 
complex, which is important for NHEJ. 
PARP-1 is an ADP-ribosylating enzyme which is activated in response to ssDNA damage and 
to some extent DSB. Once activated PARP-1 significantly enhances its intrinsic enzymatic 
activity and cleaves NAD+ into nicotinamide as well as adding extensive polymers of ADP-
ribose to glutamic acid residues of a number of target substrates [120]. By modulating the 
activity of substrates such as PARP-1 itself, histones, NF-κB, p53, topoisomerase I and 
lamin B, it can help to control vital cellular functions such as transcriptional regulation and 
cell death in addition to recruiting repair proteins to DNA damage sites [121]. Conversely, 
hyperactivation causes NAD+ depletion and subsequent prevention of ATP production. The 
eventual lack of critical intracellular energy stores results in cellular dysfunction and death. 
PARP-1 over-activation has therefore been implicated in myocardial ischaemia-reperfusion 
injury, heart failure, endothelial dysfunction, hypertension, diabetes and atherosclerotic 
plaque formation [81,122,123]. Enhanced NF-κB activity has also been shown to impair 
vascular function by PARP-1 dependent mechanisms in type 2 diabetic mouse models [124]. 
Further work involving animal models have demonstrated PARP-inhibition as protective 
against hydrogen peroxide [125] and dyslipidaemia-induced vascular dysfunction [126]. 
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PARP-1 inhibition was also found to be safe in a small cohort of patients presenting for 
urgent revascularization during ST-elevation MI, with an acute reduction in inflammatory 
markers being found [127].  
It is important to acknowledge that PARP-1 and SIRT1 are interconnected functionally and 
transcriptionally due to their common use of the substrate NAD+. Several papers have 
alluded to the cross talk between these critical DDR enzymes. SIRT1 has been shown to 
control PARP-1 activity by negatively regulating expression of the PARP-1 gene promoter. 
This prevented subsequent over-expression and PARP-1 mediated cell death in SIRT1-
deficient mouse cardiomyocytes under genotoxic stress [128]. Conversely, it has been 
postulated that activation of PARP1 depletes NAD+ levels, which inhibits SIRT1 activity 
[129,130], and therefore local supplies of NAD+ are crucial to the enzymatic activities of 
these two DDR proteins. The complex regulatory network that exists between these two 
proteins has recently been summarised using a Molecular Interaction Map by Luna et al. 
(2013) and questions the possibility of modifying chronic inflammatory pathways and 
subsequent genomic damage with SIRT1 activators or PARP-1 inhibitors [131]. 
Despite their clinical use and development in cancer therapy, comparatively little human 
clinical data currently exists on the utility of PARP-1 inhibitors in reducing atherosclerotic 
plaque burden [132]. Nevertheless, the translational value of the aforementioned studies 
support the notion that PARP-1 inhibition represents a future potential therapeutic target 
for the prevention of oxidative stress-induced vascular and myocardial dysfunction. 
DNA sequence variants in the genes encoding XRCC1 and XPD have also been shown to 
represent a higher risk for coronary atherosclerosis [133,134]. More recently, a nested case-
control study revealed a SNP in the BER gene, Nei-like DNA glycosylase 3 (NEIL3) was 
associated with an increased risk of cardiac events. The minor homozygote NEIL3 
rs12645561 SNP cohort was shown to confer a greater risk of MI, supporting the evidence 
for attenuated or defective DNA repair and atherosclerosis [135]. Genetic variation in the 
NHEJ pathway has also been associated with an increased propensity to MI, primarily 
though polymorphisms in MRE11, a subunit of the DSB sensor trimeric protein MRN [136]. 
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MMR is a highly conserved pathway that prevents the progression of insertion/deletion 
errors and base mismatches that can occur during DNA replication and recombination. The 
region of helical distortion caused by the mismatch is recognised and a sequential cascade 
results in the excision of DNA surrounding the aberrant portion. This is subsequently 
replaced by a newly synthesized section of DNA which preserves genomic stability [137]. 
Flouris et al. (2000) found LOH on hMSH2, hPMS1 and hMLH loci of DNA MMR genes in fifty 
autopsy cases of aortic atherosclerosis [138]. In addition to LOH, MSI represents phenotypic 
evidence of defective MMR and was also found in carotid [139] and cerebral atherosclerotic 
plaques [140] lending weight to such molecular alterations in the development of 
atherosclerosis.
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Figure 1.4:   Pertinent DNA repair pathways involved in atherosclerosis 
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1.5 MicroRNAs and their association with cardiovascular disease 
MicroRNAs (miRNA) should also be mentioned for their crucial role in multiple regulatory 
pathways such as cellular differentiation, proliferation, homeostasis, VSMC development 
and apoptosis [141-143]. These small non-coding regions of ribonucleic acid (RNA) are 
essential in post-transcriptional modulation of gene expression and have been implicated in 
various chronic disease states including atherosclerosis. By annealing with partial 
complementary base pairs at the 3’ and 5’untranslated target mRNA regions of protein 
coding genes or exons, miRNA cleave mRNA and repress the translational machinery 
required for protein synthesis [144]. Dysregulation of this process occurs in vascular disease, 
incriminating miRNA in atherosclerosis initiation and progression [145]. Several miRNAs 
have been specifically identified in regulating vascular inflammation, including miR-126, 
miR-31 and miR-17-3p, which contribute to the expression of adhesion molecules VCAM-1, 
ICAM-1 and E-selectin [146,147]. Atherosclerotic plaque development, stability through lipid 
uptake, subsequent monocyte/macrophage inflammation and neointimal foam cell 
accumulation has also been associated with miR-155 and miR-125a-5p [148,149].  
In addition to atherosclerosis, aberrant miRNA have also been found in other cardiac 
pathologies such as ischaemic cardiomyopathy, valvular disease, hypertrophy and post 
myocardial infarction remodeling [150]. Since a number of mi-RNAs are involved in the 
modulation of cardiovascular signal transduction, regulation of mi-RNA expression could 
prove beneficial in treating atherosclerosis. A notable example includes the association 
between miR-145 overexpression in VSMC, plaque stability and a reduction in large vessel 
atherosclerotic burden [151]. By targeting a single cell type or specific pathway, mi-RNA 
upregulation of anti-atherogenic and downregulation of pro-atherogenic pathways, 
promote an individualized therapeutic approach to treating CVD. Future challenges will 
involve improving cell-specific delivery of mi-RNA therapies to minimize potential harmful 
side effects using alternative strategies, including miRNA-enriched micro vesicles [152]. 
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1.6 PBMC as surrogate for atherosclerotic plaque 
The basic pathophysiology of atherosclerotic plaque development recognises a systemic 
inflammatory component primarily involving macrophages/monocytes and CD4+ T cells. 
Despite an improved understanding of the molecular and cellular pathways involved, the 
most reliable diagnostic tests for assessment of severity of coronary disease and response to 
therapeutic interventions remain invasive (coronary angiography, intra-vascular ultrasound 
and optical coherence tomography). Tissue material for diagnostic or prognostic analysis for 
CVD is not easily obtained and therefore the need for reliable blood based biomarkers that 
can report on disease states has grown substantially. As a result, a number of circulating 
cells are directly involved in the mechanical processes affecting myocardial as well as non-
myocardial vasculature. Specific patterns of peripheral gene expression have been reported 
in disease states such as rheumatoid arthritis, systemic lupus erythematosus and multiple 
sclerosis [153]. Due to the inflammatory potential of these conditions, immune cells in the 
vascular system may be affected. It is hypothesized that these cellular changes are the basis 
for the differential gene expression observed in RNA extracted from whole blood or from 
specific circulating cell types. As previously mentioned, the key role of inflammation in a 
number of cardiovascular conditions including essential hypertension, atherosclerosis and 
post myocardial infarction ischaemic injury and remodelling has been well established. This 
relationship makes the study of peripheral blood leukocyte or whole blood gene expression 
particularly well suited for developing more refined diagnostic and prognostic tests in 
cardiovascular medicine as circulating cells ‘sense’ the pro-inflammatory state. The greatest 
potential of this approach would be the enhancement in accurately classifying patients by 
the type and severity of their disease and to individualize the therapy based on the biology 
of the disease in an individual patient. 
Using human carotid endarterectomy specimens as a model of atherosclerosis, it has been 
previously demonstrated that human atherosclerotic plaques exhibit persistent activation of 
proteins involved in the DDR [154]. DNA damage was observed in early lesions and became 
almost universal in advanced plaques indicating that it may be detrimental in 
atherosclerosis, with a progressive increase in the expression of such proteins with 
increasing severity of plaques. Furthermore, as compared to VSMCs isolated from normal 
aortic tissue, VSMCs isolated from plaques also exhibit increased DNA damage, as well as 
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expression of transducing proteins phospho-ATM and γ-H2AX [154]. These findings may 
suggest that either the DNA repair machinery may become defective at some stage during 
the pathogenesis of the atherosclerotic lesion and may contribute to plaque instability or 
that atherogenesis may lead to up-regulation of the DNA damage machinery. In order to 
examine the physiological relevance of these findings, preliminary data collected prior to 
initiating this project has demonstrated that peripheral blood mononuclear cells (PBMCs) 
isolated from patients presenting with NSTEMI exhibit greater DNA damage when compared 
with healthy controls (figure 1.5). This suggests that a blood sample may be equally effective 
at measuring DNA damage and repair markers as a sample of plaque itself. Using 
polymerase chain reaction arrays, cultured plaque VSMCs were shown to exhibit differential 
activation of genes from multiple DNA damage and repair pathways, most notably increased 
expression of the MRN components, ATM kinase, BER and DSBR [28]. Furthermore, PBMCs 
isolated from patients with coronary artery disease have also shown evidence of DNA 
damage, including shortened telomeres and mtDNA [155]. Indeed, both telomere 
shortening and mtDNA damage were found to be associated with thin cap fibroatheroma 
further indicating peripheral blood cells may be used as markers of plaque anatomy as well 
as a surrogate for measuring atherosclerotic DDR markers.   
Despite this overwhelming evidence in support of the role of the DDR in atherogenesis, it 
remains unclear as to whether DNA damage is a manifestation of persistent DNA damage in 
the face of chronic oxidative stress, defective DNA repair, or a combination of both. 
To analyse specific gene expression in recruited patients with atherosclerotic coronary 
artery disease, published data from Gray et al. (2015) was used to identify the genes of 
interest. In the first study of its kind, oxidative stress–induced DSBs were found to be 
increased in human plaque VSMCs with DSBR being maintained. As previously mentioned, 
to determine the effect of DSBs on atherosclerosis, 2 novel transgenic mice lines expressing 
NBS1 or C-terminal deleted (ΔC) NBS1 only in VSMCs (an ATM-activation defective form of 
NBS1) were crossed  with apolipoprotein E−/− mice. The minimal SM22α promoter is 
expressed only in large artery smooth muscle cells in adult mice and is thus highly specific 
for VSMCs. Enhanced DSBR, reduced growth arrest and apoptosis was found with SM22α- 
NBS1/apolipoprotein E−/− VSMCs, whereas SM22α-(ΔC)NBS1/apolipoprotein E−/− VSMCs 
demonstrated reduced DSBR, increased apoptosis and growth arrest. Atherosclerotic 
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burden or composition was unaffected by accelerating DSBR. However, VSMC DNA damage 
reduced relative fibrous cap areas, whereas accelerating DSBR increased cap area and VSMC 
content [28]. This poses an interesting notion that accelerating or retarding DSBR has 
significant influence over atherosclerotic plaque stability due to its effect on relative fibrous 
cap thickness. To examine the differential gene expression between patients with and 
without atherosclerotic coronary disease, and correlation with in-vivo plaque 
characteristics, we used this novel study to guide gene selection. 
 
 
Figure 1.5:  Comet assay analysis of PBMCs isolated from healthy subjects (n=4) and patients 
presenting with NSTEMI demonstrating increased DNA damage in the latter (n=4). The 
comet assay or single cell gel electrophoresis assay is a sensitive technique used for 
detecting the level of DNA strand breaks in cells. Loops of DNA that lose their supercoiled 
structure are free to migrate towards the anode during electrophoresis.  Electrophoresis at 
high pH results in structures resembling comets, observed by fluorescence microscopy; the 
intensity of the comet tail relative to the head reflects the number of DNA breaks which can 
be measured visually or by using imaging software (DNA Damage and Repair in Patients with 
Coronary Artery Disease or ‘DECODE’ study protocol, as explained in the clinical 
demographics section). 
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1.7 Frequency Domain Optical Coherence Tomography (FD-OCT) use in coronary 
atherosclerosis 
In order to correlate molecular pathways and differential gene expression with the 
atherosclerotic plaque characteristics, a high resolution and validated method of assessing 
atherosclerotic plaque architecture needs to be used.  
Intravascular OCT provides a method of obtaining cross-sectional tomographic vascular 
imaging with definition that is superior to other currently available intra-coronary imaging 
modalities and is currently extensively used in interventional cardiology [156]. It acts as an 
optical analogue of intra-vascular ultrasound, where ultrasound is replaced by light that is 
reflected or back-scattered from internal structures within tissue. This 'echo time delay' 
produces a measurable signal intensity or magnitude. As the speed of light does not allow 
direct measurement of the echo time delay, interferometric techniques are employed to 
analyse the reflected light signal. Either time domain (TD-OCT) or Fourier frequency domain 
(FD-OCT) technologies are employed to create OCT images. While TD-OCT uses a moving 
mirror as its reference arm and a broadband light source, FD-OCT uses a fixed mirror with a 
variable frequency light source allowing simultaneous detection of reflections from all echo 
time delays [157]. This allows faster image acquisition rates, improved signal-to-noise ratio 
with subsequent higher quality imaging, making FD-OCT the imaging mode of preference 
(Takarada. 2010). By utilising this ultrafast frequency swept near-infrared light source to 
image the vessel, FD-OCT is able to gain axial resolutions in the region of 10 to 15µm and 
lateral resolutions of 20 to 90 µm.  The rotating fibre-optic system creates a detailed tissue 
image with a ten-fold greater resolution than that achieved with IVUS due to the shorter 
wavelength (1280-1350 nm range) of the imaging light compared with ultrasound [158-161].  
Due to the high attenuation of light by red blood cells, effective OCT requires the clearing or 
flushing of blood from the lumen prior to imaging the desired segment of vessel. The slow 
acquisition speed of TD-OCT requires proximal balloon occlusion of the coronary of interest, 
with subsequent flushing of the artery to remove blood from the field of view. This limits its 
widespread adoption because of prolonged intravascular occlusion potentiating the risk of 
coronary damage and myocardial ischaemia. In FD-OCT, a greater frame rate is achieved 
because the swept source laser can be focussed quicker than the reference mirror can be 
moved in TD-OCT. Therefore, comprehensive volumetric microscopy of the vessel can be 
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safely performed with the intra-arterial flushing of blood with a 10-15 ml bolus of crystalloid 
solution, usually radio contrast, obviating the need for balloon occlusion of the vessel [162]. 
Both TD and FD-OCT are deemed safe in assessing atherosclerotic plaque characteristics, as 
well as guiding percutaneous coronary intervention (PCI) [163]. The high definition of OCT 
imaging allows all aspects of plaque morphology to be accurately delineated including 
fibrous tissue, lipid accumulation and calcific deposition with validated and reproducible 
guidelines for intracoronary analysis [164].  
In normal vessels, the coronary artery appears as a three-layered structure with OCT. A dark 
band denotes the low signal muscular media layer between the internal elastic lamina and 
external elastic lamina. Due to its limited tissue penetration, however, OCT is not well suited 
to assess significant vascular remodelling particularly in larger calibre vessels. Fibrous 
plaques tend to appear as high signal homogenous regions with high levels of back-scatter. 
Calcifications within plaques are identified by the presence of well-circumscribed, low back-
scattering heterogenous areas (see figure 1.6). Lipid pools, in contrast, are less well 
delineated than calcification and appear as diffusely bordered, low signal areas with more 
heterogenous back-scattering than fibrous plaques, as summarised in table 1.2. In reality, an 
overlying signal-rich band usually corresponds to a fibrous cap of varying thickness [165], 
which as mentioned can influence the stability of an atherosclerotic plaque. 
Multiple studies have now demonstrated the superiority of major adverse cardiovascular 
risk reduction with OCT-guided PCI versus angiographic guided PCI alone, in both stable and 
unstable coronary cohorts [166,167]. Hence by utilising OCT to characterise the 
atherosclerotic plaque morphology in the recruited coronary artery disease cohorts, PCI can 
also be optimised to reduce the future risk of stent re-stenosis, thrombosis and mal-
apposition by using the high resolution intracoronary imaging to guide adequate stent size, 
expansion/apposition, lesion preparation as well as ensuring adequate plaque coverage. 
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Table 1.2:  Tissue characteristics observed with FD-OCT intracoronary assessment 
 
Tissue characteristics OCT characteristics 
Fibrous Homogenous                                                                                                                                          
High reflectivity                                                                                                                    
Low attenuation 
Lipid Diffuse edges                                                                                                                                   
High reflectivity                                                                                                                  
High attenuation 
Calcific Sharp well defined edges                                                                                                          
Low reflectivity (compared to IVUS)                                                                                               
Low attenuation 
Red thrombus Mass protruding into vessel lumen                                                                                   
Medium reflectivity                                                                                                                     
High attenuation 
White thrombus Luminal protrusion                                                                                                               
Medium reflectivity                                                                                                                   
Low attenuation 
Stents: Metallic                                                                                                                                              
 
              Bioresorbable 
High reflectivity                                                                                      
High attenuation 
                                                                                                                                                      
Low reflectivity (if residual polymer present)                                                                             
Low attenuation 
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Figure 1.6:  Frequency domain-optical coherence tomography imaging of atherosclerotic 
arteries demonstrating A) fibrotic plaque, B) fibrocalcific plaque, C) lipid-rich fibroatheroma 
and D) a thin-cap (arrow) fibroatheroma. Lipid/calcification arcs and fibrous cap thickness 
are marked. Images obtained from the collated database of the DECODE study registry. 
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1.8 Hypothesis, aim and objectives 
 
Hypothesis 
Patients with stable and unstable coronary artery disease display differential expression of 
genes involved in the repair of DNA damage in their circulating peripheral mononuclear 
cells, compared with patients without coronary disease, which correlate with characteristics 
of their atherosclerotic plaques. 
Aim 
The aim of this study was to assess if differential genetic biomarkers of DNA damage and 
repair activity exist between patients with stable and unstable coronary disease, as 
represented by NSTEMI, compared with patients without coronary disease. Furthermore, to 
ascertain if there is a previously unreported association with such biomarkers and in-vivo 
features of atherosclerotic plaque morphology and stability. 
Objectives 
The objectives of the study were to: 
(A) Measure and quantify the activity of upstream DNA ligases involved in BER and DSBR in 
stable and unstable coronary atherosclerosis compared with controls, by optimising 
peripheral blood mononuclear cell (PBMC) collection and isolating nuclear protein for 
downstream DNA ligase assays. 
(B) Measure the differential expression of genes encoding proteins involved in the DDR in 
patients with stable and unstable coronary atherosclerosis, compared with controls, by 
performing reverse transcription polymerase chain reactions from purified isolated RNA 
obtained from PBMC. Furthermore, assess if any genes of interest correlate with measured 
FD-OCT derived atherosclerotic plaque parameters. 
(C) Establish whether any observed differences in DNA ligase activity involved in DSBR and 
BER correlate with atherosclerotic plaque morphology, as assessed by FD-OCT performed on 
the culprit artery of recruited patients with obstructive coronary artery disease presenting 
as stable angina or NSTEMI. 
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2.0 MATERIALS AND METHODS 
 
2.1 Rationale for gene set selection and overview of experimental framework 
A sequence of steps were followed culminating in the analysis of gene expression from the 
pre-selected 22 genes of interest, between the different cohorts of patients recruited. These 
genes were selected as they were previously found to exhibit the most consistent and 
significant differential expression centred around DSBR and damage signalling, between 
cultured healthy human vascular smooth muscle cells and atherosclerotic plaques ex-vivo. 
From an original 84 gene human DNA damage signalling pathway microarray, a MetaCore 
network analysis was used to identify common upstream pathways activated in human 
atherosclerotic VSMCs [28]. Although individual components of multiple pathways involved 
in DDR and DNA repair were activated, those central to DSBR were demonstrated as most 
differentially expressed.  These selected genes of interest along with their functions are 
summarised in table 2.1. Additionally, correlation analyses were performed between 
atherosclerotic plaque morphologies in unstable and stable coronary disease and the target 
genes, as well as with DNA ligase, an enzyme with subtypes involved in base excision and 
DSB repair. 
 
Figure 2.1: Schematic representation of the experimental framework 
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Table 2.1: Summary of the functions of the 22 selected genes of interest 
Gene Full name Function 
ABL1  
[168] 
C-abl oncogene 1, non-
receptor tyrosine kinase 
Proto-oncogene involved in cell division, 
differentiation, adhesion, and stress response 
PRKDC  
[169] 
Protein kinase, DNA-activated, 
catalytic polypeptide 
Functions with the Ku70/Ku80 heterodimer 
protein in DNA double strand break repair and 
recombination 
CHEK1  
[48] 
Chk1 checkpoint homolog  
 
Serine/threonine-specific protein kinase. Initiation 
of cell cycle checkpoints, cell cycle arrest, DNA 
repair and cell death 
TP73 
[170] 
Tumour protein p73 
 
Structural resemblance to p53, considered a 
tumour suppressor. Involved in cell cycle 
regulation, and induction of apoptosis 
NLRP2 
[171] 
NLR family, pyrin domain 
containing 2 
Involved in the activation of caspase-1 by Toll-like 
receptors and in protein complexes that activate 
pro-inflammatory caspases 
MRE11A  
[38] 
MRE11 meiotic recombination 
11 homolog A  
Involved in HR, telomere length maintenance and 
DSBR. Forms a complex with RAD50 in conjunction 
with DNA ligase for NHEJ 
GADD45A  
[172] 
Growth arrest and DNA-
damage-inducible, alpha 
Activation of ionizing and non-ionizing radiation 
DNA Damage response pathway and the G2/M 
checkpoint 
ERCC2/ XPD  
[173] 
Excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 2 
Involved in transcription-coupled nucleotide 
excision repair. Unwinds DNA double helix prior to 
removal of distorted base pairing 
EBNA1BP2  
[174] 
EBNA1 binding protein 2 
 
Encodes probable ribosomal-RNA-processing 
protein EBP2 and is involved in large unit 
ribosomal biogenesis 
XRCC6  
[175] 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 6 
Involved in NHEJ encoding Ku70 protein 
Comprises two subunits functioning as a single-
stranded DNA-dependent ATP-dependent helicase 
OGG1  
[176] 
8-oxoguanine DNA glycosylase Involved in BER by excision of 8-oxo-guanine, a 
mutagenic by-product of exposure to reactive 
oxygen species  
DDB1 
[177] 
Damage-specific DNA binding 
protein 1 
Nucleotide excision repair and core component of 
E3 ubiquitin ligase complexes 
MLH3  
[178] 
MutL homolog 3 (E. coli) 
 
Maintenance of genomic integrity during DNA 
replication and meiotic recombination 
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ATM  
[48] 
Ataxia telangiectasia mutated 
 
Serine/threonine protein kinase acting as a signal 
transducer in DSBR. Phosphorylates key proteins 
involved in DNA damage checkpoints leading to 
cell repair, senescence, arrest or apoptosis. 
RAD50  
[39] 
RAD50 homolog  Forms a complex with MRE11A and NBS1 - the 
MRN complex instrumental in DSBR signalling 
XPA  
[179] 
Xeroderma pigmentosum, 
complementation group A 
Interacts with ERCC1, RPA1 and XAB2 to mediate 
DNA damage recognition and repair. Nucleotide 
excision repair 
ERCC1  
[180] 
Excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1  
Forms an enzyme complex with ERCC4 to catalyse 
DNA repair and recombination. Integral in NER 
and some functions in DSB, both NHEJ and HR 
CDK7  
[181] 
Cyclin-dependent kinase 7 
 
Activates cyclin-associated kinases CDK1, CDK2, 
CDK4 and CDK6 by threonine phosphorylation 
regulating cell cycle progression. Component of 
TFIIH involved in transcription initiation and DNA 
repair. Nucleotide excision repair 
BRCA1  
[182] 
Breast cancer 1, early onset 
 
Repair of DNA double-strand breaks, 
ubiquitination and transcriptional regulation 
GTSE1 
[183] 
G2 and S-phase expressed 1 
 
Expressed in S and G2 phases of the cell cycle. In 
response to DNA damage, encoded protein 
accumulates in the nucleus, binds the tumour 
suppressor protein p53, diverting it out of the 
nucleus and reducing subsequent apoptosis 
RBBP8  
[184] 
Retinoblastoma binding 
protein 8 
Regulates cell proliferation and modulates the 
function of BRCA. Involved in DSBR 
SUMO1  
[185] 
Small ubiquitin modifier 1 
 
The encoded protein (SUMO1) is involved in 
nuclear transport, transcriptional regulation, 
apoptosis and protein stability 
 
 
2.2 Collection and handling of blood samples 
All blood samples were obtained from consenting patients in a sterile manner and using 
equipment in accordance with St. Peter’s Hospital trust policy (REC Reference 13/LO/0238).  
Intra-procedural blood samples were obtained using intra-arterial radial or femoral sheaths 
(Terumo), depending on the route of coronary angiographic access. Control samples of 
blood were taken from patients referred for coronary angiography with no evidence of 
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epicardial atherosclerotic coronary artery disease. Approximately 50ml of blood was 
collected in ethylenediaminetetraacetic acid (EDTA) containing vacutainers and immediately 
refrigerated at 4⁰C with additional ice packs until peripheral blood mononuclear cell 
isolation, and plasma/ serum separation, which was performed within 4 hours of collection. 
 
2.3 Peripheral blood mononuclear cell (PBMC) isolation 
With this technique the density of whole blood was adjusted to a level considerably higher 
than that of the PBMCs and was layered beneath a 1.078 g/ml density barrier. The PBMCs 
subsequently floated to the surface, with the additional benefit of the low-density barrier 
acting as a "buffer-zone" which "washed” the PBMCs free of soluble plasma proteins and 
particulate contaminants such as platelets at the same time as they were purified from 
other blood cells. It has previously been demonstrated that using Becton Dickinson CPT 
tubes, which contain a FICOLL™ Hypaque™ density barrier, PBMC preparations contain 59.4 
± 7.5% T-lymphocytes, 21.2 ± 6.3% monocytes, 12.3 ± 6.3% natural killer cells, 5.3 ± 2.0% B-
lymphocytes, and 0.1 ± 0.2% granulocytes/polymorphonuclear leukocytes (i.e. minimal 
neutrophilic contamination) [186]. We used this as a guide to optimise our technique in 
obtaining PBMCs for downstream applications. 
A modified version of this flotation technique utilising Dulbecco’s Modified Eagle Medium 
(DMEM) to create working and density barrier solution was used and optimised for PBMC 
collection. 40 ml of blood was collected in 10 ml K2 EDTA vacutainers and mixed by 
inversion. A working solution of 1.216 g/ml OptiPrep (Sigma-Aldrich) was prepared by 
mixing 26.7 ml of OptiPrep (equivalent to 4 volumes; 1.32 g/ml) with 13.3 ml of DMEM. A 
density barrier of 1.078 g/ml was then prepared by mixing 16.4 ml of working solution (5 
volumes; 1.216 g/ml) with 31.6 ml of DMEM (9.6 volumes; 1.007 g/ml). For each sample to 
be processed, 11 ml of the 1.078 g/ml barrier was pipetted into a 50 ml Falcon tube. Two 
halves of each sample (approximately 20 ml each) were transferred to two 50 ml skirted 
Falcon tubes containing 5.4 ml of working solution and the solutions mixed by inversion. 
This adjusted the density of the combined blood and working solution (normally 1.06 g/ml) 
to approximately 1.096 g/ml to allow a flotation method of separating PBMC from the 
unwanted constituents of whole blood.  
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11 ml of the diluted blood was carefully pipetted under 11 ml of the created density barrier 
in the 50 ml tube (4 tubes used for each 40 ml blood sample). For the layering, a pipette gun 
was fitted with a 5 ml stipette and set to dispense by gravity rather than by motor. The 
pipette tip was placed at the bottom of the tube and blood was dispensed very slowly 
allowing for migration of erythrocytes to the bottom of the Falcon tube. 0.6 ml of DMEM 
was then carefully layered on top of the density barrier to facilitate harvesting of the PBMCs 
and avoiding banding at the water/air interface following centrifugation. The tubes were 
then centrifuged at 700 x g for 20 minutes at room temperature with no brake. The PBMC 
layer was transferred into a 20 ml Universal tube diluted with at least an equal volume of 
phosphate-buffered solution (PBS) and mixed by inversion prior to centrifugation at 500 x g 
for 10 minutes at room temperature, with the brake on. The liquid was aspirated and the 
cell pellet re-suspended in 3.5 ml of complete media, comprising of 90% DMEM and 10% 
foetal bovine serum (FBS). A further solution of 2 x freezing media was prepared comprising 
1 ml of FBS, 1 ml dimethyl-sulfoxide (Sigma-Aldrich) and 3 ml complete media. 3.5 ml of this 
2 x freezing media was added to the complete media/cell pellet suspension. 1 ml aliquots 
were placed into cryo-vials stored at -80⁰C for further use. 
 
 
 
Figure 2.2: PBMC separation following centrifugation into different bands according to 
whole blood constituents [186]. 
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2.4 Nucleic acid protein extraction 
 
NE-PER (Thermo Scientific) Nuclear and Cytoplasmic Extraction Reagents were used to allow 
step-wise separation and preparation of nuclear and cytoplasmic extracts from the isolated 
PBMCs. Non-denatured, active proteins were obtained in a purified form. Addition of the 
Cytoplasmic Extraction Reagent I (CER I) and Reagent II (CER II) to a cell pellet caused cell 
membrane disruption and release of cytoplasmic contents. After recovering the intact nuclei 
from the cytoplasmic extract by centrifugation, the proteins were extracted out of the nuclei 
with the Nuclear Extraction Reagent (NucER). This protocol was used as extracts obtained 
with this method generally have less than 10% contamination between nuclear and 
cytoplasmic fractions, which has been shown to have sufficient purity for most downstream 
applications such as enzyme activity studies. All centrifugation steps were performed at 4⁰C 
with cell samples and extracts kept on ice to minimise the freeze-thaw effect. 
A 1 ml cryovial of PBMC sample was transferred to a 1.5 ml microtube and centrifuged at 
500 x g for 3 minutes to yield a cell pellet. The freezing medium was carefully removed using 
a pipette and PBS was added with repeat centrifugation at 500 x g to wash the pellet. 200 µl 
of ice-cold CER I was added to the pellet with 100 X concentration protease inhibitor cocktail 
(Thermo Scientific) as per protocol. The tube was vortexed vigorously for 15 seconds to fully 
suspend the pellet and incubated on ice for 10 minutes. 11 µl of CER II was added to the 
mix, vortexed for 5 seconds on the highest setting and incubated on ice for 1 minute. 
Following repeat vortexing for 5 seconds, the tube underwent centrifugation at 16,000 x g in 
a micro-centrifuge. The cytoplasmic extract supernatant was immediately transferred to a 
clean pre-chilled microtube. The resultant insoluble fraction containing the sample nuclei 
was suspended in ice-cold NucER with the corresponding volume of 100 x concentration 
protease inhibitor. The tube was then vortexed on the highest setting for 15 seconds. The 
sample was placed on ice and vortexed for 15 seconds every 10 minutes, for a total of 40 
minutes. Following this, the tube underwent centrifugation at 16,000 x g for 10 minutes 
with the subsequent supernatant, comprising of nuclear extract, being transferred to a clean 
pre-chilled microtube. The extract was stored in a -80⁰C freezer until further use. 
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2.4.1 Protein quantification 
The BCA Protein Assay kit (Thermo Scientific) was used to perform accurate protein 
quantifications prior to DNA ligase activity determination. The assay is a detergent-
compatible formulation based on bicinchoninic acid (BCA) for the colourimetric detection 
and quantitation of total protein. This method combines the reduction of Cu2+ to Cu1+ by 
protein in an alkaline medium (the biuret reaction) with the highly sensitive and selective 
colourimetric detection of the cuprous cation (Cu1+) using a reagent containing BCA [187]. 
The purple-coloured reaction product of this assay is formed by the chelation of two 
molecules of BCA with one cuprous ion. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is nearly linear with increasing protein concentrations over a 
broad working range (20-2000 μg/mL). Given that the final colour continues to develop, the 
BCA method is not a true end-point. However, following incubation, the rate of continued 
colour development was sufficiently slow to allow multiple samples to be assayed together. 
 
The macromolecular structure of protein, the number of peptide bonds and the presence 
of four particular amino acids (cysteine, cystine, tryptophan and tyrosine) are reported to 
be responsible for colour formation with BCA [188]. Studies with di-, tri- and tetra-peptides 
suggest that the extent of colour formation is caused by more than the mere sum of 
individual colour-producing functional groups [188]. Accordingly, protein concentrations 
generally are determined and reported with reference to standards of a common protein 
such as bovine serum albumin (BSA). Therefore, a series of dilutions of known 
concentration are prepared from the common protein and assayed alongside the unknown 
sample concentration before the concentration of each unknown(s) is determined based on 
the standard curve.  
 
Ampoules of BSA at 2 mg/mL in 0.9% saline and 0.05% sodium azide were used to prepare a 
set of common protein standards. BCA working reagent was prepared by mixing 50 parts of 
BCA reagent A, containing sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1 M sodium hydroxide, with 1 part of BCA reagent B comprising 4% 
cupric sulphate. The diluent used was nuclear extraction reagent previously used for 
protein extraction. 10 µl of the each standard was pipetted onto a microplate well with 
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subsequent wells being filled with 10 µl of the protein sample. Each sample had triplicate 
measurements. 200 µl of working reagent was added to each well and the microplate was 
mixed thoroughly on a plate shaker for 30 seconds. The plate was then covered and 
incubated at 37⁰C for 30 minutes. The plate was cooled to room temperature and the 
absorbance was measured at 562 nm on a FLUOstar Omega multi-mode microplate reader 
(BMG Labtech). The average 562 nm absorbance measurement of the Blank standard 
replicates was subtracted from the 562 nm measurement of all other individual standard 
and sample replicates. A standard curve was prepared by plotting the average Blank-
corrected 562 nm measurement for each BSA standard versus its concentration in μg/ml, 
and subsequently used to determine the protein concentration of each sample analysed. 
 
2.5      DNA ligase assay 
 
DNA ligase assays were performed on the nuclear extract samples by Dr. Ruan Elliott 
(University of Surrey) in vitro. A double stranded oligonucleotide was formed within 
microplate wells from three oligonucleotide strands (Sigma Aldrich), the structure of which 
is outlined in Figure 2.3. REP03 which contains an amino C6 group is required to covalently 
attach the oligonucleotide to the microplate well, LIG02 which contains a 3’ fluorescein 
group is used for detection and REP04 forms the complementary strand. DNA ligase 
covalently attaches the LIG02 strand to the REP03 strand, therefore DNA ligase activity is 
required to covalently attach the fluorescein containing double stranded oligonucleotide to 
the microplate well. 
 
Figure 2.3: Representation of the double-stranded oligonucleotide structure formed in the 
microplate well for DNA ligase assay. DNA ligase covalently ligates the LIG02 strand to the 
REP03 strand attaching the fluorescein containing strand to the microplate well. It is this 
fluorescent signal that is detected by anti-fluorescein antibody and the absorbance read 
using a microplate reader. 
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REP03 was diluted to 25 nM final concentration in phosphate buffer (at 0.1 M, pH 8.5) and 
100 µl was added to each well of a 96 well plate (Nunc immobilizer plate, Fisher scientific). 
The plate was subsequently sealed and incubated for 24 hours at 4⁰C. The solution was 
then removed prior to the wells being washed twice with PBS containing 0.1% tween 20 
(PBS-T). LIG02 and REP04 were each diluted to 25 nM final concentration in a hybridisation 
buffer (6 x saline sodium citrate buffer, 5 mM EDTA, 0.1% tween 20, 0.5% BSA). After 
adding 100 µl of both the REP04 and LIG02 solution to each well, the plate was sealed and 
placed in a hybridisation oven for 5 minutes at 90⁰C after which the temperature was 
incrementally lowered by 1⁰C per minute to 55⁰C. The temperature was kept constant at 
55⁰C for 10 minutes before being lowered by1⁰C per minute and maintained for 10 minutes 
at 45⁰C. The plate was further cooled to 30⁰C by 1⁰C per minute and then allowed to cool 
to room temperature. The solution was decanted from the wells which were then washed 
thrice with PBS-T. 
A standard curve for DNA ligase enzyme activity was created by making up samples of T4 
DNA ligase diluted with repair buffer to give final concentrations of 0U/100µl, 
0.00004U/100µl, 0.00012U/100µl, 0.00037U/100µl, 0.0011U/100µl,0.0033U/100µl and 
0.03U/100µl. 100µl of each of the standard solutions or sample nuclear extracts were 
added in duplicate to the wells before sealing the plate and incubating for an hour at 37⁰C. 
Again, the solution was decanted before the wells were washed four times with PBST.  
The double stranded oligonucleotide was then denatured using 200 µl per well of alkaline 
denaturing buffer solution (0.1 x saline sodium citrate buffer, 0.1 M NaOH). The plate was 
sealed and then incubated for 15 minutes at 75⁰C. 125 µl per well of neutral denaturation 
buffer (0.1 x saline sodium citrate buffer, 0.1% sodium dodecyl sulphate) was then added 
prior to sealing the plate and incubating for 10 minutes at 75⁰C. Following this, the solution 
was removed; neutral denaturation buffer was added a second time and the plate was 
sealed and incubated for a further 10 minutes at 75⁰C. After washing twice with PBS-T the 
plate was tapped dry. 
Fluorescein levels remaining in the wells were then detected by adding 100 µl per well of 
anti-fluorescein antibody coupled with horseradish peroxidase (diluted 1:10,000 in PBS-T 
with 1% BSA). The plate was sealed and then incubated for one hour at room temperature. 
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After solution removal, the wells were washed three times with PBS-T and the plate was 
tapped dry. 100 µl per well of TMB microwell peroxidase substrate (Insight Biotechnology 
Ltd.) was added and incubated at room temperature until sufficient colour development 
occurred. The reaction was stopped by adding 100 µl per well of 2 M phosphoric acid. 
Absorbance was read using the FLUOstar omega multi-mode microplate reader at 450 nm. 
 
 
2.6    RNA isolation and Quantitative Reverse Transcription Polymerase Chain Reaction   
(qRT-PCR).   (Performed by Core Lab Qiagen, Hilden, Germany) 
 
2.6.1    RNA isolation 
 
The Qiagen RNeasy Mini Kit was used for RNA isolation. The RNeasy procedure combined 
the selective binding properties of a silica-based membrane with microspin technology. A 
specialized high-salt buffer system allowed up to 100 μg of RNA longer than 200 base 
sequences to bind to the RNeasy silica membrane. After lysing and homogenising the PBMC 
samples in the presence of a highly denaturing guanidine-thiocyanate containing buffer, 
Buffer RLT (Qiagen), RNAses were immediately inactivated to ensure purification of the 
intact RNA. The addition of ethanol provided appropriate binding conditions for the RNA to 
bind to the silica membrane within the RNAeasy Mini spin column, with the contaminants 
effectively washed away.  
 
All laboratory materials and surfaces used were pre-cleaned with 70% ethanol and 
RNAaseZap, an RNAse decontamination solution (ThermoFisher Scientific). Cryovials of the 
PBMC sample of interest were first centrifuged for 5 minutes at 300 x g in an RNAse free 
microtube to yield a cell pellet, which was harvested by careful removal of the supernatant. 
600 µl of Buffer RLT was added to the pellet and vortexed to facilitate lysis and 
homogenisation. 1 volume of 70% ethanol was added to the homogenised lysate and mixed 
thoroughly by vortexing. Up to 700 µl of the sample was transferred to an RNeasy spin 
column placed in a 2 ml collection tube and centrifuged for 15 seconds at 9000 x g. This was 
repeated until the all of the lysate had been centrifuged. The flow-through was discarded 
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after each successive aliquot. 
 
The spin column membrane was then washed with 700 µl of Buffer RW1, a washing 
solution containing guanidine salt and ethanol (Qiagen), and centrifuged at 9000 x g for 15 
seconds. As previously, this was repeated for successive aliquots to ensure all of the lysate 
was filtered. The flow through was discarded and the spin column was removed from the 
collecting tube. 500 µl of Buffer RPE, a milder washing solution used to remove traces of 
salts used earlier in the protocol, was added to the spin column and centrifuged as before. 
The flow through was discarded and after the addition of a further 500 µl of Buffer RPE, the 
centrifugation step was repeated for 2 minutes to ensure that the membrane was dry of 
any residual ethanol potentially interfering with downstream applications. The spin column 
was attached to a new 1.5 ml collection tube having discarded the old tube. 50 µl of RNAse-
free water was then added directly to the spin column membrane and centrifuged at 9000 
x g for 1 minute to elute the RNA. RNA quality and concentration were determined by using 
a Nanodrop spectrophotometer to measure the concentration and OD260/280 values of the 
samples and an Agilent RNA TapeScreen (Agilent Technologies) to check RNA quality. For 
the integrity measurement, 1 μl of the total RNA was analysed with a RNA ScreenTape 
using an Agilent TapeStation.  
 
The steps involved in the workflow are summarised in figure 2.4. 
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Figure 2.4:  Workflow outlining the steps involved in isolating purified RNA 
 
(Reproduced with permission from the qRT-PCR Qiagen protocol) 
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2.6.2    Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
 
Real-time qRT-PCR is currently regarded as the most sensitive and reliable method for gene 
expression analysis. Its wide dynamic range made real-time RT-PCR the preferred choice for 
the study allowing the simultaneous quantification of both rare and abundant genes in the 
same sample. A customised RT2 Profiler PCR array for the 22 genes of interest was compiled 
along with 5 housekeeping genes and a set of controls to monitor for genomic DNA (gDNA) 
contamination, reverse transcription (RTC) quality and real-time positive PCR efficacy, 
making a total of 32 genes analysed. The Positive PCR Controls (PPC) tested the efficiency of 
the polymerase chain reaction itself using a pre-dispensed artificial DNA sequence and the 
primer set that detects it. The DNA contamination control assay (GDC) was designed to 
determine if gDNA was present in the sample at an amount that may affect PCR results. The 
GDC primers specifically detected non-transcribed genomic DNA contamination with a high 
level of sensitivity. The Reverse Transcription Control (RTC) specifically tested the efficiency 
of the Qiagen RT² First Strand Synthesis Kit reaction with a primer set to detect template 
synthesized from the kit's built-in external RNA control. 
 
The house-keeping genes selected were actin beta (ACTB), beta-2-microglobulin (B2M),    
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine   
phosphoribosyltransferase 1 (HPRT1) and ribosomal protein P0 (RPLP0). Due to their 
expression at relatively constant levels under most experimental conditions, these genes 
were deemed ideal for normalization and use as a reference. Their use as endogenous 
controls have been extensively reported and validated in the literature [189-191], and by 
utilising multiple stable reference genes for qRT-PCR, the accuracy of gene expression data 
was optimised. An average expression of all 5 house-keeping genes were used as internal 
control.  
 
A two-step quantitative RT-PCR process was adopted comprising an initial conversion of the 
isolated RNA into first strand complementary DNA (cDNA). The cDNA templates then 
underwent standard qPCR for monitoring the expression of the target genes, all performed 
in one batch, to ensure removal of any batch effect. 
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Qiagen RT2 First Strand Kit was used for cDNA synthesis which initially eliminated genomic 
DNA contamination followed by the reverse transcription stage. A gDNA elimination 
mixture was prepared by adding 6 µl of Buffer GE2, a gDNA elimination buffer, to RNAase 
free water. This was added to 100 ng of the purified sample RNA to make a volume of 14 µl 
and incubated at 37⁰C for 5 minutes followed by immediately placing on ice for at least 1 
minute. 6 µl of RE3 Reverse Transcriptase Mix (consisting of random hexamers, oligo-dT, 
de-oxyribose nucleoside triphosphates and reverse transcriptase enzyme) was added to 
each 14 µl of gDNA elimination mixture for a final volume of 20 µl. This was incubated at 
42⁰C for 15 minutes to allow reverse transcription and immediately heated at 95⁰C for 5 
minutes to stop the reaction. The first strand cDNA yielded was placed on ice in preparation 
for qPCR. 
 
The samples were arranged in a 384-well plate in a 32 gene by 12 sample configuration, 
with each sample array being performed in triplicates (see Appendix A). 0.7 ng of cDNA was 
used for each qPCR reaction and each well was made up of a 10 µl mix of RT2 SYBR Green 
qPCR mastermix, RNA-ase free water and RT2 qPCR primer for each gene of interest. The 
nuclease-free tube was placed in an Applied Biosystems 7900HTthermal cycler and heated 
for 95⁰C to activate the HotStart DNA Taq polymerase. A subsequent cycling program of 
incubating the sample mix at 95⁰C for 15 seconds, followed by 60⁰C for 40 seconds to allow 
binding of the primers, polymerisation and fluorescence data collection was repeated 40 
times. 
 
The steps involved in the qRT-PCR process are summarised in figure 2.5. 
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Figure 2.5:  Workflow outlining the steps involved in qRT-PCR.  
Adapted from Overbergh at al. (2003) [192] 
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2.7    qRT-PCR data analysis 
 
The PCR Array Data Analysis Web Portal, as noted below, was used to perform the 
calculations and interpretation of the control wells upon including cycle threshold (Ct) data 
from a real-time instrument, along with individual gene expression analysis. 
(http://www.sabiosciences.com/pcrarraydataanalysis.php)  
 
The following sequence was used for robust data normalisation and analysis as per the 
delta delta Ct method (ddCt): 
 
1. All Ct values reported as greater than or equal to 35, or as n/a (not detected) to 35, were 
considered as a negative call. 
 
2. The threshold cycle values of the control wells were examined 
a. Genomic DNA Control (GDC): 
1. The Ct GDC was calculated 
2. If the value was greater than 35, then the level of genomic DNA contamination 
was deemed too low to affect gene expression profiling results and no further 
action was required. 
3. If the value was less than 35, then genomic DNA contamination was evident. 
 
b. Reverse Transcription Control (RTC): 
Any impurities in the RNA sample that affect the reverse transcription of the RT2 First 
Strand Kit’s built-in external RNA control could also affect the reverse transcription of the 
messages of interest. Hence the following method was used to ensure an adequately 
purified RNA sample was used for cDNA synthesis.  
 
1. (Average Ct value of RTC) – (Average Ct value of PPC) was calculated. 
2. If this value was less than 5, then no inhibition was apparent. If this value was 
greater than 5, then evidence of impurities that inhibited the reverse transcription 
phase of the procedure was evident. 
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c. Positive PCR Control (PPC): 
The average Ct PPC value should be 20 ± 2 on each PCR Array and should not have: 
1. Varied by more than two cycles between PCR Arrays being compared. 
2. Larger differences in average Ct PPC values between samples indicated the 
presence of different amounts of PCR amplification inhibitors in each sample and 
that all of the RNA samples required further purification. 
3. An average value of Ct PPC that was consistently greater than 22 for all of the 
samples may have indicated a problem with the cycling conditions or may simply be 
indicative of the relative sensitivity of the instrument used. 
 
3. The delta or difference in Ct(dCt) for each pathway-focused gene in each plate was 
calculated: 
 
dCt = (Ct Gene of Interest) – (Ct Average of Housekeeping Genes). The arithmetic mean is 
used for calculating the average housekeeping gene Ct. 
 
4. As triplicate assays were performed for each sample, the average dCt value of each gene 
(each well) across those triplicate arrays for each treatment group was calculated. 
 
5. The ddCt for each gene across two groups or PCR Arrays was then calculated as below: 
 
ddCt = dCt (group 2) -dCt (group 1). Group 1 was the control and Group 2 was the 
experimental 
 
6. The fold-change was subsequently calculated for each gene from group 1 to group 2 as 
2(-ddCt). 
 
7. Relative expression was displayed as 2^-dCt or 2 –dCt for the purposes of visualising 
differential expression between cohorts. 
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2.8    Optical Coherence Tomography (OCT) analysis of coronary arteries 
 
The principles and rationale behind frequency domain OCT (FD-OCT) have been described 
elsewhere. FD-OCT was performed prior to target epicardial vessel percutaneous coronary 
intervention (PCI), after maximal vessel dilatation with intra-coronary glyceryl tri-nitrate. A 
Dragonfly Duo OCT Imaging catheter (St. Jude Medical ILUMIEN OPTIS PCI Optimisation 
system, MN, USA) was used, utilising a 2.7-French monorail delivered through a 6-French 
guide catheter over a standard 0.014-inch intra-coronary guidewire. This rapid exchange 
monorail imaging catheter was connected to a central console containing the light source, 
image processing software and imaging display (ILUMIEN OPTIS PCI Optimisation system). 
The data was acquired in a secure format and analysed off-line, with quantitative 
measurements made for endoluminal area, endoluminal diameter, as well as plaque 
parameters including arcs of lipid, calcium, fibrous cap thickness and segments of thin-
capped fibroatheroma (TCFA) defined as lipid-rich plaques with an arc >90⁰ with an 
overlying fibrous cap thickness ≤ 80µm [193]. 
 
Full OCT runs were performed for target vessels, with analyses performed at 1mm 
segments throughout the whole vessel of interest. Analytical software was used for 
accurate quantification of calcium and lipid arcs. Three fibrous cap measurements were 
taken for each lipid arc, with the average value calculated for the segment reviewed. Mean 
calcium, lipid arcs and fibrous cap thickness were then calculated for each vessel analysed. 
Sample runs of 36 OCT analyses were performed independently by two trained observers 
with measurements on luminal areas, plaque characteristics and dimensions being highly 
reproducible between observers as demonstrated by Brown et al (2016) [193]. The 
remaining OCT analyses were performed by a trained observer following confirmation of 
measurement reproducibility by assessment of congruity of thirty OCT samples. As shown 
in table 2.2, very high intraclass correlation coefficients (ICC) were calculated for these 
thirty OCT runs, to demonstrate the reliability of measurements for each of the 
atherosclerotic plaque parameters between the trained observer and training supervisor 
(see figures 2.6 to 2.9, produced with the aid and expertise of Dr. Iain McLaurin, March 10, 
2019). 
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For each target lesion vessel, the luminal area (mm2) defined as the area bounded by the 
luminal border, arc of lipid (degrees) measured using the centre of the lumen as the angle 
point for lipid, arc of calcification (degrees) measured using the centre of the lumen as the 
angle point for calcification and fibrous cap thickness (μm) was recorded as demonstrated 
in figure 2.10.    
 
The SYNTAX score, an objective and validated method of measuring the angiographic 
complexity of coronary artery disease, was calculated by a trained observer following 
extensive training at a core lab facility (Papworth Hospital NHS Foundation Trust, 
Cambridge, UK) and subsequent completion of the online training module. [194]. 
 
To understand the angiographic morphological characteristics of the culprit lesion, a 
summary of the American Heart Association lesion classification (AHA - an angiographical 
method of assessing the risk, complexity and subsequent success rate of a treating a 
coronary lesion) is provided below and was recorded for each patient undergoing FD-OCT 
guided PCI: 
 
Type A lesion: < 10mm, discrete, concentric readily accessible, < 45 degree angle smooth 
contour, little or no calcification, less than totally occluded, not ostial, no major side branch 
involvement, absence of thrombus. 
 
Type B1 lesion - One of the following characteristics: 10 to 20 mm, eccentric, moderate 
tortuosity of proximal segment, irregular contour, presence of any thrombus grade, 
moderate or heavy calcification, total occlusion less than 3 months old, ostial lesion or 
bifurcation lesion requiring two guide-wires. 
 
Type B2 lesion: Two or more of the characteristics mentioned for type B1 lesions 
 
Type C lesion: > 20 mm diffuse, excessive tortuosity of proximal segment, total occlusion 
greater than 3 months old and/or bridging collaterals inability to protect major side 
branches, degenerated vein graft with friable lesions. 
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Table 2.2:  Intraclass correlation coefficients of the three atherosclerotic plaque parameters 
for the sample of thirty FD-OCT runs between the two trained observers/raters 
 
Method ICC Probability  ICC Lower CL ICC Upper CL 
Average Calcium Arc (Degrees) 0.999 <.0001 0.999 1.000 
Average Lipid Arc (Degrees) 0.978 <.0001 0.955 0.990 
Average Fibrous Cap Thickness 
(µm) 
0.984 <.0001 0.966 0.992 
 
 
 
 
 
 
 
 
Figure 2.6:  Boxplot demonstrating close agreement between the two observers, or raters 
for arc of calcium for the 30 FD-OCT samples. The box represents the interquartile range 
between Q1 and Q3 (25th and 75th percentiles). The line within the box represents the 
median and the mean average value is represented by the black diamond. The whiskers 
show the range of the data and outliers are denoted as round black dots (above or below 
1.5 times the interquartile range). 
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Figure 2.7:   Bland-Altman plot where the X-axis is the mean average of each of the two 
trained observers, or raters’ ratings for arc of calcium for the 30 sample FD-OCT runs. The Y-
axis are the differences between the raters’ values. To aid in the understanding of the 
measures in the plots, on the Y-axis, three additional lines are superimposed. These lines 
are the mean average difference between the raters (blue line) and measure of the lower 
and upper confidence limits of the mean average difference (dashed red lines). The plot 
also indicates only one difference in measurement outside the 95% confidence limits (1.96 
multiplied by the standard deviation). 
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Figure 2.8:  Boxplot and Bland-Altman plot demonstrating the close concordance between 
arc of lipid measurements between the two trained raters for the 30 FD-OCT samples. 
Almost all measurements lie within the 95% confidence interval (± 1.96 standard 
deviations). Only one value is apparent on the Bland-Altman plot where there was a large 
discrepancy between raters. A larger number of outliers are evident on the boxplot with 
both plots suggesting a slight positive skew to the data. 
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Figure 2.9:   Boxplot and Bland-Altman plots demonstrating a high level of congruence of 
measurements of fibrous cap thickness between the two trained raters for the sample 30 
FD-OCT runs. As such, there are no points that fall outside the confidence limits. The 
boxplots also indicate that the spread of measurements are close to a normal distribution. 
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Figure 2.10:  Fibrous cap measurement of the well delineated hyper-dense band seen 
overlying a lipid pool, obtained from the average of three measurements taken depicted by 
the yellow, white and green lines using the ILUMIEN OPTIS PCI Optimiser system (St. Jude 
Medical). The lower panel represents a longitudinal view of the same coronary artery of 
interest. 
 
 
2.9 Future applications - Monocyte isolation and enrichment 
(Performed with the aid of Dr. Gillian Wallis – University of Surrey) 
 
As monocytes have been implicated in the atherosclerotic process, a test PBMC sample was 
used to ascertain if an enriched sample of monocytes could be reliably isolated for future 
downstream genomic experiments such as signal transduction, monocyte activation as well 
as cytokine secretion. Further monocyte extractions were not performed on account of 
limited enrichment of samples analysed, limited resources and time. However, it does 
provide the basis for directing future experiments. 
Using the Pan Monocyte Isolation Kit (Miltenyi Biotech), human monocytes were isolated by 
depletion of non-monocytes (negative selection). Non-monocytes such as T cells, natural 
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killer cells, B cells, dendritic cells and basophils were indirectly magnetically labelled with a 
cocktail of biotin-conjugated monoclonal antibodies, as primary labelling reagent, and anti-
biotin monoclonal antibodies conjugated to MicroBeads, as the secondary labelling reagent. 
The magnetically labelled non-monocytes were depleted by retaining them on a MACS 
Column (Miltenyi Biotech) in the magnetic field of a MACS separator, while the unlabelled 
monocytes passed through the column for collection. 
Prior to MACS separation, 75 ml of MACS BSA Stock Solution containing PBS and 10% bovine 
serum albumin was added to 1.45 L of autoMACS Rinsing Solution to create the MACS 
Separation Buffer. Miltenyi Biotech Dead Cell Removal Kit was used to further remove 
contaminants before monocyte isolation. Once thawed from -800C, the PBMC sample of 
interest was centrifuged at 300 x g for 5 minutes and the supernatant was aspirated. The 
cell pellet was re-suspended in 30 µl buffer. 10 µl of FcR blocking reagent (human 
immunoglobulin) was added along with 10 µl of Biotin-Antibody cocktail. The solution was 
mixed well and incubated at 40C for 5 minutes. A further 30 µl of buffer was added with 20 
µl of Anti-Biotin MicroBeads. This was mixed well and incubated for an additional 10 
minutes at 40C. The MS column was placed in the magnetic field of the MiniMACS Separator 
and prepared by rinsing with 500 µl of buffer. The cell suspension was applied onto the 
column and the flow-through was collected containing unlabelled cells representing the 
enriched monocyte fraction. The column was further washed three times with 500 µl of 
buffer. The column was then removed from the separator and the magnetically labelled 
non-monocyte cells were flushed out with the application of 1 ml of buffer and compression 
of the plunger.   
Fluorescence-activated cell sorting (FACS) flow cytometry was subsequently used for 
monocyte labelling. Mouse IgG2A anti-human CD14-fluorescein isothiocyanate (FITC) 
(Autogen Bioclear), mouse IgG2A FITC (Coulter) for isotype, mouse IgG1 anti-human CD163-
APC and mouse IgG1 APC (R&D) for isotype antibodies were used for detection of enriched 
monocytes. 
After suspension by gently pipetting up and down, the cells were transferred to a 12ml 
polypropylene tube and counted. 1.5 ml Eppendorf tubes were used to aliquot 
approximately 1 x 106 cells into three tubes with tube 1 to contain unlabelled cells, tube 2 to 
contain CD14 and CD163 labelled cells and tube 3 to harbour both CD14 and CD163 
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isotypes. 1 ml of assay buffer (PBS and 0.1% BSA) was added to each tube and spun at 
13,000 x g for 2 minutes at 40C. The cells were re-suspended in 100 µl of assay buffer and 
labelled with the appropriate antibody for incubation on ice for 20-30 minutes. The cells 
were re-centrifuged at 13,000 x g for 2 minutes at 40C after which the supernatant was 
removed. The cells were subsequently re-suspended in 500 µl of ice cold 1 x BD CellFix (BD 
Biosciences) prepared from 10 x concentrate, before transferring to a FACS tube. An extra 
500 µl of CellFix was added and the samples were read using a BD FACSCalibur flow 
cytometer (BD Biosciences, Singapore). 
 
2.10 Statistical analyses 
In the absence of published data regarding parameters such as DNA ligase activity in 
humans with and without atherosclerosis, a sample size of 30 patients per group was 
recommended to detect an effect size of 0.9 with a power of 80% and 2-tailed α of 0.05 (Dr. 
Huihai Wu, personal communication, December 11, 2015). In total, 126 patients were 
recruited to comfortably allow for three cohorts of at least 30 patients even with sample 
exclusions.  Statistical analysis was performed using SAS, version 9.4 (SAS Institute, Cary, 
North Carolina).  
 
2.10.1 Continuous variables  
Normal quantile-quantile plots of clinical variables were used to assess the assumption that 
the variable parameters were normally distributed within each of the three groups, and 
boxplots were used to visually assess the plausibility of equal variance. Since ANOVA and t-
tests are fairly robust to violations of the homogeneity of variance assumption if group sizes 
do not vary drastically (the ratio of largest to smallest group size was 1.4, which is inside the 
acceptable range as verified by statistical support; Professor Simon Jones, personal 
communication, August 15, 2016), no continuous variables failed the assumption checks 
because of unequal variance.  
However, values for left ventricular ejection fraction, triglycerides and glucose within each 
group appeared to deviate greatly from normality. Hence, for these three variables, non-
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parametric methods were used. The Kruskall-Wallis test (one-way ANOVA on ranks) was 
used for the overall comparison between all three groups, and the Dwass, Steel, Critchlow-
Fligner (DSCF) method was used for the pairwise comparisons. For all other continuous 
variables, one-way ANOVA was used for the overall comparison, and Tukey’s method was 
used for all post-hoc pairwise comparisons.  
DNA ligase activity and gene expression data were analysed using a one-way ANOVA and 2-
tailed paired or unpaired t-test as appropriate. As the distribution of DNA ligase activity 
from PBMC in humans has not been previously documented, observing the relative 
normality of data from the recruited controls supported the statistical methods employed. 
The three FD-OCT plaque parameters measured, calcium arc, lipid arc and fibrous cap 
thickness, were compared between coronary cohorts using one-way ANOVA. Correlation 
between FD-OCT plaque parameters, gene expression and DNA ligase activity was analysed 
using Spearman rank correlation co-efficient. Spearman rank was used to reduce the effects 
of outliers and was deemed more suitable to assess a monotonic relationship than 
Pearson’s correlation after review of the study design, data, review of the literature, 
objectives and consultation with statistical support. In addition, given the paucity of data 
surrounding DNA ligase activity in humans and the novelty of the data collected in this 
regard, combined with the number of assumptions that would require fulfilment for 
Pearson’s to be reliably used, Spearman’s rank was preferred. All p values <0.05 were 
considered statistically significant. All data was presented as mean ± standard deviation or 
standard error mean as appropriate. Intraclass correlation coefficients were calculated using 
a two-way ANOVA model. 
 
2.10.2 Categorical variables 
For all categorical data that formed binary variables, a logistic regression model was fitted 
and a likelihood ratio test (based on the Chi-squared distribution) was used to calculate the 
p-value for the overall comparison of the three groups. For the pairwise comparisons, the 
Bonferroni correction was used to account for multiple testing. 
Four of the binary variables (Clopidogrel / Prasugrel / Ticagrelor use, Aspirin use, Statin use 
and A2RB use) had groups with either 100% as expected peri-percutaneous intervention, or 
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0% of patients answering yes. Maximum likelihood estimation is known to perform poorly 
when sample size is small or events are rare, and results are often biased and consequently 
the maximum likelihood estimate will not exist. To avoid this problem, penalized likelihood 
(the Firth method) was used instead. 
For both culprit vessel and AHA lesion classification (angiographical method of assessing the 
risk, complexity and subsequent success rate of a treating a coronary lesion), Fisher’s exact 
test was used in place of a Chi-squared test, given the sample size being small enough to 
accurately allow this along with expected counts likely to be low. For culprit vessel, an 
overall p-value for the null hypothesis of independence was calculated, as well as p-values 
for each individual vessel based on grouping categories to form 2 x 2 contingency tables. For 
example, the p-value for ‘Proximal Left Anterior Descending’ was calculated from a 2 x 2 
table of ‘Proximal Left Anterior Descending’ vs ‘Not Proximal Left Anterior Descending’. For 
AHA lesion classification, type C lesion group only contained one patient and therefore 
analysing this category separately would be unreliable. To avoid this, AHA lesion types B and 
C were combined, yielding a p-value obtained from a 2 x 2 contingency table of ‘lesion type 
A’ against ‘not lesion type A’ (or lowest risk of coronary lesion/highest chance of successful 
treatment, against moderate or higher risk/lowest chance of successful treatment).  This is 
appropriate as type A lesions are the least complex coronary lesions to treat, whereas type 
B and C lesions represent a higher complexity of disease. For the purposes of this study, it 
was therefore appropriate to combine type B and C lesions as one group representative of a 
slightly higher complexity of coronary disease patients. 
For Syntax Score (a validated method of angiographically assessing the complexity of 
coronary artery disease) one-way ANOVA was used to calculate p-values. Again all p values 
<0.05 were deemed statistically significant. 
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3.0 CLINICAL DEMOGRAPHIC OF PATIENTS RECRUITED 
 
3.1 Study registration and background 
The DNA Damage and Repair in Patients with Coronary Artery Disease (DECODE) study was a 
prospective observational cohort study approved by the NRES Committee South East Coast-
Surrey, UK (REC Reference: 13/LO/0238, IRAS Project ID: 120221) and is registered at 
ClinicalTrials.gov (NCT02335086). All participants gave written informed consent prior to 
enrolment (appendix B refers to the patient information sheet, appendix C to the consent 
form completed by all participants and appendix D confirms ethical approval). Patients 
undergoing percutaneous coronary intervention (PCI) with either stable angina or non-ST 
elevation myocardial infarction (NSTEMI) at St. Peter’s Hospital, Chertsey, for a de novo 
obstructive coronary arterial lesion were prospectively enrolled. Elective age and sex 
matched outpatients being investigated with coronary angiography and who were found to 
have unobstructed epicardial coronary arteries were also recruited and served as the 
control arm of the study. Matching was performed by one-to-one frequency, with an age 
difference of +/- 5 years deemed suitable to allow for recruitment within the study time 
constraints.  
 
3.2 Exclusion criteria 
Clinical exclusion criteria were inability to provide informed consent, age 80 years old and 
above, presentation with ST-elevation MI, decompensated heart failure, hypotension, 
refractory ventricular tachycardia, diabetes mellitus, left ventricular ejection fraction (LVEF) 
less than or equal to 35%, prior coronary revascularisation, peripheral vascular disease, 
previous history of cerebrovascular disease, previous history of any malignancy, any form of 
surgery up to three months prior to enrolment, active inflammatory disorders, bleeding 
diathesis, known allergy, hypersensitivity, or contraindication to aspirin, heparin, or 
thienopyridines, and life expectancy less than 1 year.  
Age over 80 years old was deemed suitable for exclusion based on previous published data 
on the effects of ageing on DNA damage and repair mechanisms, which may confound some 
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of gene expression results obtained. Goukassian et al. (2000) demonstrated a significant 
decrease with ageing in the repair rates of thymine dimers. There was also an age-
associated decrease in the protein levels of ERCC excision repair 3, DNA Repair Protein 
Complementing XP-A (XPA), and tumour protein p53 that participate in NER. Furthermore 
with age, induction of p53 after UV irradiation was significantly reduced. This age-associated 
decrease in the repair of UV-induced DNA damage, particularly in the over 80 year old 
group, results at least in part from decreased levels of proteins that participate in the repair 
process [195]. Increased point mutations have been also observed with ageing due to a 
decline in efficient BER [196] as well as NER [197]. Other age-related changes affecting DNA 
repair include inefficient MMR which can lead to microsatellite instability, point mutations 
and potentially, to increased frequency of loss of heterozygosity [198,199]. More error-
prone and inefficient NHEJ may result in a higher level of point mutations and genomic 
alteration [200]. As mutated cells enter the G2 stage of the cell cycle, the usage of sub-
pathways of DSBR may also change, reducing efficiency of homologous recombination 
between sister chromatids, forming pathways for progression of mutagenic genomic 
instability [201].  Higher levels of exposure to DNA damage possibly arise from an 
uncontrolled production of free radicals by ageing mitochondria and a decreased 
antioxidant defence mechanism. An age-related decline has also been observed in DSBR and 
phosphorylated histone H2A variant (γ-H2AX), a sensitive indicator of the DSB response 
[202]. However, there is currently no published data demonstrating the effects of ageing 
specifically on DNA ligase activity to date.  
Given the demographic of coronary artery disease patients in the recruitment catchment 
area, lowering the age of exclusion may have significantly hindered recruitment, in turn 
jeopardising appropriate numbers of patients recruited to the coronary patient groups. For 
this reason, the recruited patients were age and sex matched to within a 5 year differential 
on an individual basis, within each cohort. 
ST-segment elevation MI patients typically present with an occluded coronary artery that 
necessitates immediate revascularisation. It was deemed inappropriate to perform 
intracoronary imaging during emergency presentation, in addition to frequency domain 
optical coherence tomography (FD-OCT) providing little information, for the purpose of this 
study, regarding plaque composition which would require disruption following restoration 
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of coronary flow in an occluded culprit artery. Significant hypotension, as defined as 
persistent systolic blood pressure of less than or equal to 90mmHg during the 
revascularisation procedure despite appropriate fluid resuscitation, along with refractory 
ventricular tachycardia were all deemed ineligible for recruitment based on unsuitability of 
intracoronary imaging for the purpose of study recruitment in a high risk unstable patient.   
Diabetes mellitus patients have an increased risk of cardiovascular disease, however, were 
excluded from participation from the DECODE study based on published data indicating 
their propensity to DNA damage and consequent increased risk for breast, pancreatic and 
colorectal cancer [203]. This elevated risk is primarily attributed to increased production of 
reactive oxygen species and subsequent increased levels of DNA damage, along with 
reduced capacity to combat this hyperglycaemic induced oxidative stress [204]. Previous 
studies have alluded to both the increased exposure to oxidative DNA damage along with 
decreased efficiency of DNA repair machinery through DNA repair enzymes endonuclease III 
and formamidopyrimidine-DNA glycosylase (205-207], although DNA ligase activity has not 
been specifically assayed in such a population. The literature would therefore suggest that 
all forms of diabetes mellitus represent a pathophysiological state of DNA damage as well as 
oxidative stress, which can lead to various types of mutations in the genetic material of the 
cell potentially confounding down-stream assays of gene expression and DNA repair activity 
in our study [208]. Similarly, underlying inflammatory conditions such as rheumatoid 
arthritis, vasculitis or active colitis, although known to have an increased predisposition to 
coronary disease, were excluded due to the underlying influence of the non-coronary 
inflammatory pathology on down-stream assays. 
Patients with LVEF less than or equal to 35% categorise this group into severe left 
ventricular systolic impairment or, if symptomatic, as having heart failure with a significantly 
reduced ejection fraction. The literature supports the notion of elevated levels of oxidative 
stress and subsequent higher levels of circulating DNA damage in affected populations. In 
support of this notion, a small study in patients with severely reduced LVEF with a left 
ventricular assist device as a bridge to either transplant or destination therapy outlined 
defective DNA repair and higher levels of oxidative stress compared to healthy volunteers 
[209]. In addition to a higher baseline level of DNA-damaging oxidative stress not necessarily 
related to atherosclerosis, severe LV impairment may have multiple aetiologies including 
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non-ischaemic causes which may directly impact on gene expression and ligase assay 
results. For these reasons, it was deemed necessary to exclude patients with low LVEF. 
In order to remove the variable nature of treatment for any pre-existing vascular condition 
which may influence the underlying cellular processes being studied, patients who had 
previously undergone revascularisation or had a history of peripheral or cerebrovascular 
disease patients were excluded. This ensured that patients without pre-treated vascular 
disease, either with optimal secondary preventative medication or interventional therapies, 
were recruited for study. 
A previous history of malignancy would exclude potential participants given that a 
confirmed underlying DNA mutational process would certainly confound gene expression 
analyses. Many of these patients would also be on concurrent chemotherapeutic and 
radiotherapy regimens which would further alter innate DNA damage and repair assays. 
Patients with an underlying bleeding disorder (such as a thrombophilia or haemophilia), 
allergy, hypersensitivity or contraindication to dual antiplatelet therapy were excluded on 
the basis that optimal care post percutaneous coronary intervention may not be possible 
without requisite antiplatelet therapy on-board. There is little evidence for high dose single 
antiplatelet therapy post PCI, and therefore patients with a true contraindication to aspirin 
or an additional antiplatelet agent may have required de-sensitisation therapy or alternative 
revascularisation strategies for their obstructive coronary lesions, hence were deemed 
ineligible for recruitment. 
Angiographic exclusion criteria were left main coronary artery stenosis ≥ 50%, as these 
patients were typically discussed at a multi-disciplinary meeting if they were clinically stable 
prior to embarking on a revascularisation strategy. Patients undergoing coronary artery 
bypass surgery (CABG) planned within one year of the procedure were excluded as they did 
not usually proceed to have PCI with stents, and anatomical conditions precluding FD-OCT 
such as significant tortuosity, severe calcification and chronic total occlusion of the artery of 
interest which prevent the passage of the FD-OCT catheter beyond the lesion(s) of interest. 
 
 
65 
 
3.3 Inclusion criteria 
In patients with stable angina, FD-OCT assessment was undertaken for any lesion with 
angiographical luminal stenosis greater than or equal to 70% and any lesion with a luminal 
stenosis less than or equal to 70% but fractional flow reserve measurement (FFR) less than 
0.80. Fractional flow reserve is a method of assessing the physiological severity of a 
coronary lesion by measuring the ratio of maximal blood flow distal to a stenosis to normal 
maximal flow in the vessel of interest. Data exists to support revascularisation in patients 
with an FFR measurement less than 0.80 primarily driven by a reduction in the risk of future 
ischaemia driven target lesion revascularisation [210]. In patients with NSTEMI, the culprit 
lesion was defined according to electrocardiographic criteria (ST segment shift or T-wave 
inversion) and angiographic appearances (point of maximal stenosis, luminal irregularities 
consistent with ulceration, or filling defects consistent with thrombus). The SYNTAX score 
was subsequently calculated by a trained observer using the online calculation tool [194].  
To understand the differential DNA-repair related gene expression and DNA ligase activity 
profile between patients with de novo stable and unstable coronary artery disease, using 
NSTEMI as a presentation of the latter, compared with control patients without 
atherosclerotic epicardial coronary disease, an aggressive attempt to exclude all disease 
processes which may influence the underlying DNA signalling and repair processes was 
made. By doing so, the aim was to reduce the likelihood that any differential expression was 
due to other disease processes separate to the atherosclerotic state. Prior to recruitment, it 
was accepted that certain variables such as smoking, which significantly increases 
cardiovascular and cancer risk, has been shown to affect DNA damage and repair by 
elevated oxidative free radical production, would not be excluded from recruitment as this 
would significantly limit the potential for completing patient recruitment within the 
specified time-frames. It was also accepted that thus far, DNA ligase activity and the pre-
selected genes for differential expression have not been studied in such a population and 
therefore merit further evaluation given the high proportion of smokers with coronary 
disease.  
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3.4 Clinical demographics of recruited cohorts 
In total, 126 patients were recruited comprising 42 patients presenting with NSTEMI, 49 
patients with stable angina and 35 patients serving as controls, which comfortably fell 
within the pre-determined minimal numbers required for the desired effect size, power and 
significance level. During qRT-PCR for the gene expression analyses of the study, some 
patient samples had to be excluded on account of either poor quality RNA isolation or 
genomic DNA contamination for accurate reverse transcription (three NSTEMI, one stable 
angina and two controls). Similarly, two NSTEMI, five stable angina and three control patient 
samples were excluded from DNA ligase assays on account of nuclear protein content 
deemed too low for accurate ligase measurement, as summarised in table 3.1.  
 
Table 3.1:  Summary of RT-PCR and DNA ligase assay sample exclusions and resultant 
sample sizes 
 
Original sample 
size 
NSTEMI 
   42 
STABLE 
   49 
CONTROL 
    35 
Why excluded? 
Final sample 
size for gene 
expression 
   39    48     33 After quality control of RT and qPCR, samples 
deemed unsuitable for analysis 
Final sample 
size for mean 
DNA ligase 
assay 
   40    44     32 Low protein concentration excluded as 
deemed unsuitable for DNA ligase assay.  
One sample from stable angina group with 
no peripheral blood mononuclear cell sample 
 
 
The baseline clinical demographics and significance calculations for each variable for 
patients recruited to each cohort are summarised in table 3.2 
There was no significant difference in the age or sex of patients recruited between the 
cohorts as demonstrated in figure 3.1. There was a slightly lower mean age of patients 
recruited to the control group (57.8 ± 9.74 years), however this fell within the acceptable 
parameters for overall one-to-one matching and this difference was not statistically 
significant (one-way ANOVA p=0.06). Post-hoc paired analysis between cohorts also 
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revealed no statistically significant difference. A higher proportion of patients recruited to 
both stable angina and NSTEMI coronary disease groups were male as expected for 
coronary artery disease patient studies, given the higher prevalence of symptomatic and 
asymptomatic CVD in men [1,2]. 
The mean body mass index (BMI), LVEF, total cholesterol, non-high density lipoprotein (non-
HDL), triglyceride levels and fasting glucose were all equivocal between groups with no 
significant overall or post-hoc paired difference seen between the cohorts (see figures 3.2 
and 3.3). Two patients (one from each NSTEMI and stable angina group) had an elevated 
glucose reading of greater than 7.0 without symptoms of diabetes (polyuria, polydipsia, 
weight loss or fatigue), however repeat fasting glucose and glycated haemoglobin levels 
were within acceptable parameters to categorise them as non-diabetic and subsequently 
continue with inclusion in the study (see figure 3.4).   
Interestingly, the mean total cholesterol for controls was higher than those seen in the 
stable angina and NSTEMI groups (5.06 ± 0.76 vs 4.48 ± 1.24 and 4.74 ± 1.20 respectively). 
This could be accounted for by the initiation of statins post preliminary investigations for 
chest pain in the case of stable angina, and immediately post diagnosis of a confirmed 
NSTEMI as part of standard secondary preventative medications, both prior to coronary 
angiography and peripheral venesection. This is supported by the significantly higher use of 
statins pre and post angiography in the coronary disease patient groups and higher levels of 
hyperlipidaemia in both the stable angina and NSTEMI groups compared with controls. For 
the purpose of the study, patients were recorded as being hyperlipidaemic if they were 
known to be diagnosed at the time of recruitment, as documented in their medical records 
and verified with their General Practitioner, based on primary prevention guidelines.  
Historically, a large disparity persisted between different guidelines with regards to which 
patients are truly hyperlipidaemic. For those patients without a prior diagnosis, based on 
AHA guidelines, a threshold of total plasma cholesterol greater than or equal to 5.2 
mmol/litre, with concomitant non-HDL levels greater than 4.0 mmol/L was used to identify 
new hyperlipidaemics, although more recently there has been a shift towards absolute risk 
evaluation with pooled cohort equations [211]. Although previous European Society of 
Cardiology guidelines suggest aiming for a target total plasma cholesterol level of less than 
5.0 mmol/L and low density lipoprotein (LDL) level less than 3.0 mmol/L, there remains 
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some discrepancy as to when to initiate lipid lowering therapy. The current Joint British 
Society and European guidelines share the American approach by recommending that 
plasma cholesterol and its differential fractions are part of a scoring system to ascertain a 10 
year and life time CVD risk, rather than using them in isolation to determine whether to 
initiate lipid lowering therapy [212,213].  
A higher proportion of patients with known hyperlipidaemia were recruited to the stable 
angina group, compared with the NSTEMI and control cohorts. Our recruitment criteria 
stipulated no prior history of treated or untreated vascular disease, and therefore all 
participants with CVD were presenting with their first cardiovascular event. NSTEMI is 
frequently an acute presentation of unstable coronary disease and therefore patients in this 
cohort frequently are not known to have established CV risk factors when compared with 
stable angina patients, who are therefore more likely to have a pre-determined diagnosis of 
hyperlipidaemia. Recent data suggests differential lipid profiles between different 
presentations of coronary disease [214]. The range of total cholesterol between the patients 
recruited to the stable angina group was higher than the other two cohorts as 
demonstrated in figure 3.2, however, despite higher variability in values obtained, this did 
not translate to a statistically significant difference in values between groups.      
Haemoglobin levels and platelet counts were not significantly different between groups. 
Mean total white cell counts (WCC) were elevated in the NSTEMI group compared with the 
stable angina and control groups. It is accepted that during acute myocardial infarction, an 
elevated WCC indicating a systemic inflammatory response forms part of the healing 
process. Further studies have demonstrated that an elevated WCC is also an independent 
predictor of long term mortality in both STEMI and NSTEMI patients [215.216]. For this 
reason, NSTEMI patients by definition, have biomarker evidence of myocardial necrosis and 
subsequent inflammation is likely to have triggered an elevated white cell response, 
compared with the more stable coronary group and patients without coronary artery 
disease. The range of values for both parameters were higher in the NSTEMI group as 
demonstrated in figure 3.5. 
Hypertension, a positive family history of first degree relatives diagnosed with CVD prior to 
the age of 60 years old and a history of smoking (within the last 40 years) were all 
significantly higher in the NSTEMI and stable angina groups compared with the controls. 
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There was no difference between a diagnosis of hypertension and a family history of CVD 
between patients recruited to the NSTEMI or stable angina group, but a significantly higher 
proportion of those presenting with NSTEMI had a history of smoking compared with stable 
angina.  
Secondary prevention medications post MI include aspirin, a second antiplatelet agent 
typically Clopidogrel, Ticagrelor or Prasugrel, an angiotensin converting enzyme-inhibitor 
(ACE-I) or angiotensin 2 receptor blocker (A2RB), statin and a beta-blocker. Most patients 
with stable angina will also be placed on these medications, if tolerated. Therefore, 
significant differences in cardiovascular protective medications are noted between cohorts 
as demonstrated in table 3.2. 
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Table 3.2:  Summary of the baseline clinical characteristics of patients recruited 
 
 NSTEMI  
(n = 42) 
STABLE  
(n = 49) 
CONTROL  
(n= 35) 
P value 
Age (mean ± SD) 58.1 ± 12.14 62.6 ± 9.74 57.8 ± 9.74 0.06 
 58.1 ± 12.14 62.6 ± 9.74  0.08 
 58.1 ± 12.14  57.8 ± 9.74 >0.99 
  62.6 ± 9.74 57.8 ± 9.74 0.13 
Gender (% M/F) 33 / 9  
(78.6% / 21.4%) 
34 / 16  
(69.4% / 30.6%) 
20 / 15  
(57.1% / 42.9%) 
0.13 
     
BMI (kg/m2) 27.74 ± 5.93 27.04 ± 4.20 27.73 ± 4.60 0.75 
     
LV ejection fraction (%) 62.1 ± 4.5 62.2 ± 7.2 63.6 ± 3.6 0.36 
     
Total Cholesterol (mmol/L) 4.74 ± 1.20 4.48 ± 1.24 5.06 ± 0.76 0.07 
 4.74 ± 1.20 4.48 ± 1.24  0.52 
 4.74 ± 1.20  5.06 ± 0.76 0.43 
  4.48 ± 1.24 5.06 ± 0.76 0.06 
Non-HDL (mmol/L) 3.62 ± 1.00 3.13 ± 1.05 3.51 ± 0.80 0.15 
     
Triglycerides (mmol/L) 1.47 ± 1.20 1.41 ± 1.07 1.56 ± 0.95 0.68 
     
Glucose (mmol/L) 5.36 ± 0.92 5.18 ± 0.76 5 ± 0.56 0.15 
     
Haemoglobin (g/L) 14.49 ± 1.26 14.27 ± 0.98 14.3 ± 1.02 0.60 
     
White cell count (x109/L) 8.74 ± 2.76 7.31 ± 1.72 7.08 ± 1.61 <0.01 
 8.74 ± 2.76 7.31 ± 1.72  <0.01 
 8.74 ± 2.76  7.08 ± 1.61 <0.01 
  7.31 ± 1.72 7.08 ± 1.61 0.89 
Platelets (x109/L) 233.9 ± 55.8 246 ± 62.3 253.9 ± 53.6 0.32 
     
History of smoking (n, %) 29 (69.0%) 19 (38.8%) 13 (37.1%) 0.01 
 29 (69.0%) 19 (38.8%)  0.04 
 29 (69.0%)  13 (37.1%) 0.02 
  19 (38.8%) 13 (37.1%) >0.99 
Hypertension 22 (52.4%) 29 (59.2%) 8 (22.9%) <0.01 
 22 (52.4%) 29 (59.2%)  >0.99 
 22 (52.4%)  8 (22.9%) 0.03 
  29 (59.2%) 8 (22.9%) <0.01 
Hyperlipidaemia (n, %) 12 (28.6%) 28 (57.1%) 7 (20.0%) <0.01 
 12 (28.6%) 28 (57.1%)  0.02 
 12 (28.6%)  7 (20.0%) >0.99 
  28 (57.1%) 7 (20.0%) <0.01 
Family history of IHD (n, %) 20 (47.6%) 24 (49.0%) 8 (22.9%) 0.03 
 20 (47.6%) 24 (49.0%)  >0.99 
 20 (47.6%)  8 (22.9%) 0.08 
  24 (49.0%) 8 (22.9%) 0.05 
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 NSTEMI 
(n=42) 
STABLE 
(n=49) 
CONTROL 
(n=35) 
 
P value 
Aspirin use (n, %)* 42 (100%) 49 (100%) 11 (31.4%) <0.01 
 42 (100%) 49 (100%)  >0.99 
 42 (100%)  11 (31.4%) <0.01 
  49 (100%) 11 (31.4%) <0.01 
Clopidogrel / Prasugrel / 
Ticagrelor use (n, %) 
42 (100%) 49 (100%) 1 (2.9%) <0.01 
 42 (100%) 49 (100%)  >0.99 
 42 (100%)  1 (2.9%) <0.01 
  49 (100%) 1 (2.9%) <0.01 
Beta-blocker use (n, %) 38 (90.5%) 40 (81.6%) 7 (20.0%) <0.01 
 38 (90.5%) 40 (81.6%)  0.71 
 38 (90.5%)  7 (20.0%) <0.01 
  40 (81.6%) 7 (20.0%) <0.01 
Statin use (n, %) 42 (100%) 47 (95.9%) 9 (25.7%) <0.01 
 42 (100%) 47 (95.9%)  >0.99 
 42 (100%)  9 (25.7%) <0.01 
  47 (95.9%) 9 (25.7%) <0.01 
ACE-inhibitor use (n, %) 40 (95.2%) 32 (65.3%) 7 (20.0%) <0.01 
 40 (95.2%) 32 (65.3%)  0.01 
 40 (95.2%)  7 (20.0%) <0.01 
  32 (65.3%) 7 (20.0%) <0.01 
A2RB use 2 (4.8%) 7 (14.3%) 0 (0%) 0.05 
 2 (4.8%) 7 (14.3%)  0.52 
 2 (4.8%)  0 (0%) >0.99 
  7 (14.3%) 0 (0%) 0.27 
Calcium antagonist use 2 (4.8%) 12 (24.5%) 6 (17.1%) 0.02 
 2 (4.8%) 12 (24.5%)  0.06 
 2 (4.8%)  6 (17.1%) 0.29 
  
  
12 (24.5%) 6 (17.1%) >0.99 
 
NSTEMI=Non-ST elevation myocardial infarction; HDL=High density lipoprotein; 
IHD=Ischaemic heart disease; LV=Left ventricle; ACE=Angiotensin converting enzyme; 
ARB=Angiotension-2 receptor blocker. Where rows of values are repeated, this purely for 
ease of interpretation for paired analyses where the ANOVA is significant or close to 
significant (p<0.05). E.g. White cell count of patients in NSTEMI versus stable groups (8.74 ± 
2.76 vs 7.31 ± 1.72, p<0.01) and NSTEMI versus control (8.74 ± 2.76 vs 7.08 ± 1.61, p<0.01).  
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Figure 3.1:  Boxplots demonstrating the distribution of age and BMI between cohorts recruited 
for the DECODE study. The box separating the whiskers represents the interquartile range, with 
the solid line indicating the median value. Whiskers demonstrate the minimum and maximum 
data points that are not deemed outliers. Diamond denotes the mean value and the circle 
represents an outlier, defined as greater than 1.5 times the interquartile range above and below 
the third and first quartiles respectively. 
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Figure 3.2: Box and whisker plots demonstrating the distribution of LVEF and total 
cholesterol by group. Diamond represents mean value. Outliers are denoted by a circle as 
per the standard definition previously stated. The lowest recorded LVEF Is 37%, with only 
two further recorded values ≤ 50% (normal being ≥ 55%). The distribution of LVEF indicate a 
deviation from normality, hence non-parametric methods were adopted for further analysis.  
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Figure 3.3: Box and whisker plots demonstrating the distribution of non-HDL and 
triglyceride levels by cohorts recruited. The mean values are represented by diamonds and 
outliers by circles. In total, there were 7 outliers with triglyceride levels greater than 3.0, 
and given the skewed distribution of data, non-parametric analyses were used for 
triglyceride levels.  
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Figure 3.4:  Boxplots outlining the distribution of fasting glucose levels and platelet counts 
of patients recruited by group. Diamond represents mean values and circles indicate outliers 
as per the standard aforementioned definition. Glucose tended to deviate from a normal 
distribution, hence non-parametric analytical methods were used. 
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Figure 3.5:  Boxplots demonstrating the distribution of haemoglobin levels and total white cell 
counts by group. Diamonds represent mean values and circles outliers. No significant difference 
was seen between haemoglobin levels between the cohorts, however a significantly higher WCC 
was found for patients presenting with NSTEMI compared with stable angina and the control 
group. The mean WCC for all groups were within the normal range. 
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3.5 Angiographic parameters 
For each of the patients recruited to the study with obstructive coronary artery disease 
requiring PCI, coronary angiographic data was collated. Intracoronary imaging using 
frequency domain optical coherence tomography (FD-OCT) was used to ascertain 
atherosclerotic plaque characteristics in the coronary disease cohorts (NSTEMI and stable 
groups). As previously mentioned, FD-OCT uses near infra-red light that is reflected or back-
scattered from internal structures within tissue. This 'echo time delay' produces a 
detectable signal intensity or magnitude and is indirectly measured by using interferometric 
techniques to analyse the reflected light signal. A high resolution intracoronary image is 
produced which can be interpreted to reveal constituent atherosclerotic plaque 
characteristics. 
The angiographic and procedural characteristics for those patients recruited to both 
coronary disease cohorts are summarized in table 3.3.  
There were no significant differences between groups for the culprit vessel affected, 
although the mid left anterior descending artery was the commonest site of maximal 
stenosis requiring treatment. There was also no significant difference between AHA 
coronary lesion classification between groups, with the predominant lesion treated in both 
cohorts being type B (either 1 or 2).  
To further understand the complexity of coronary lesions, the SYNTAX score was calculated 
and found to be low in both groups, however, was significantly higher in the NSTEMI group 
(10.3 ± 5.5 vs 7.8 ± 4.4, p=0.02). As previously mentioned, the SYNTAX score provides an 
angiographic grading tool to quantify the complexity of coronary disease and incorporates a 
scoring system applied to features such as the location of the lesion, presence of significant 
calcification, lesion length, bifurcation, chronically occluded arteries, tortuosity and 
presence of thrombus to arrive at an overall score. It is predictive of major adverse 
cardiovascular events (MACE) in multi-vessel disease and published data would suggest that 
patients with an overall low score (less than or equal to 22) have an improved outcome with 
revascularisation by PCI compared to CABG. Intermediate scores (23-32) have an equivalent 
composite risk of MACE with PCI compared with CABG and the highest tertile group, scoring 
greater than 32 tended to have better outcomes with surgery, at the expense of an 
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increased risk of stroke [217]. One could surmise that despite a low overall level of 
complexity of coronary artery disease in patients recruited to both groups, the NSTEMI 
individuals tended to have a slightly higher complexity of disease.  
 
3.6 Atherosclerotic parameters as measured using FD-OCT 
Despite none of the individual atherosclerotic parameters measured with FD-OCT being 
significantly different between groups, a trend towards a higher mean lipid arc (122.7 ± 71.3 
vs 97.5 ± 63.9, p=0.09) and a thinner fibrous cap overlying a lipid pool were present in the 
NSTEMI group (152.7 ± 56.5 vs 175.5 ± 46.8, p=0.06), both features of a higher risk plaque. It 
is worth noting that a higher calcium arc may represent an increased degree of calcification 
within the artery of interest and therefore score higher as a feature of the SYNTAX score in 
the NSTEMI patients, although this was not significantly different between the coronary 
disease groups. The remaining two parameters measured; fibrous cap thickness and lipid 
arc, cannot be viewed via angiography alone but play an important role in the 
characterisation of vulnerable plaque, the prevalence of which is higher in patients 
presenting with a myocardial infarction [17]. 
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Table 3.3: Summary of angiographic and procedural characteristics of stable angina and 
NSTEMI patients recruited 
Variable 
 
Stable Angina (n=49) NSTEMI (n=42) p value 
Culprit Vessel 
Proximal Left Anterior Descending 
 
Mid Left Anterior Descending 
 
Circumflex Artery 
 
Right Coronary Artery 
 
15 (30.6%) 
 
18 (36.7%) 
 
6 (12.2%) 
 
10 (20.5%) 
 
8 (19%) 
 
19 (45.2%) 
 
2 (4.8%) 
 
13 (31%) 
0.28 
0.23 
 
0.52 
 
0.28 
 
0.33 
 
AHA Lesion Classification 
A 
B 
C 
 
17 (34.6%) 
31 (63.3%) 
1 (2.1%) 
 
12 (28.6%) 
30 (71.4%) 
0 (0%) 
 
0.65 
 
 
Syntax Score 7.8±4.4 
 
10.3±5.5 
 
0.02 
 
OCT Parameters (mean ± standard deviation) 
Arc of Lipid (degrees) 
 
Arc of Calcium (degrees) 
 
Fibrous cap thickness (µm) 
 
97.5 ± 63.9 
 
51.6 ± 45.4 
 
175.5 ± 46.8 
 
 
122.7 ± 71.3 
 
63.6 ± 47.0 
 
152.7 ± 56.5 
 
0.09 
 
0.23 
 
0.06 
 
Univariate scatterplots were performed to visualise the spread of values obtained for each 
patient’s atherosclerotic parameter within each group. It is important to note that fibrous 
cap thickness can only be measured overlying a lipid pool, hence measurements are only 
performed where there is a lipid arc over which the cap thickness can be obtained. In 
vessels with purely fibrotic lesions where a lipid arc cannot be identified, no fibrous cap 
measurements can therefore be made, using the validated approach to FD-OCT 
interpretation [218]. In total, this occurred in eight patients comprising of six patients in the 
stable angina and two patients in the NSTEMI group.  The distribution and accompanying 
explanation of the plots can be viewed in figures 3.6 to 3.9 inclusive. 
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Figure 3.6: Univariate scatterplot outlining the distribution of FD-OCT derived calcium arcs 
in individual patients recruited to the NSTEMI and stable angina cohorts. Labels merely 
correspond to anonymised patient identifiers for the purpose of categorisation for the 
study. For example, PBMC represents an abbreviation for peripheral blood mononuclear 
cell, MM represents the initials of the primary investigator and LAD is a further anonymised 
identifier within the encrypted database. Labels are not shown for all patients with a 
calcium score of zero and in densely concentrated regions to preserve legibility of the plot 
for ease of interpretation. Red diamonds represent the mean value. Similar distributions 
and clustering are noted, with a non-significant higher mean calcium arc seen in the NSTEMI 
compared with stable angina cohort (63.6 ± 47.0 vs 51.6 ± 45.4, p=0.23). 
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Figure 3.7: Scatterplot demonstrating the distribution of individual lipid arcs in patients 
recruited to the NSTEMI and stable angina cohorts as assessed with FD-OCT. Labels are as 
previously stated. Patient labels were removed for all patients a lipid arc of zero and within 
densely concentrated regions to ensure clear and legible plots for interpretation. Mean lipid 
arc was demonstrated to be higher in the NSTEMI group, however did not achieve statistical 
significance (122.7 ± 71.3 vs 97.5 ± 63.9, p=0.09). The range and distribution of the data 
does not appear to vary drastically between groups, however, more patients had fibrotic 
obstructive lesions only in the absence of significant calcium or lipid arcs, yielding a higher 
number of patients with zero lipid arc in the stable group. 
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Figure 3.8:  Scatterplot displaying the distribution of fibrous cap thickness values obtained 
for patients presenting with NSTEMI and stable angina undergoing FD-OCT guided PCI. As 
mentioned, fibrous cap thickness can only be measured overlying a lipid pool. Labels are as 
previously stated. Despite statistical significance not being reached, there was certainly a 
trend towards thinner fibrous caps within the NSTEMI group (152.7 ± 56.5 vs 175.5 ± 46.8, 
p=0.06), with a clustering of values below 150 μm. Given the higher lipid content of 
atherosclerotic plaques in the NSTEMI cohort, a higher proportion of patients had a fibrous 
cap to measure compared to the stable angina group. 
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Figure 3.9:  Scatterplot displaying the distribution of SYNTAX scores for patients recruited to 
NSTEMI and stable angina cohorts. A significantly higher mean score was demonstrated with 
the NSTEMI group indicating a higher angiographically complex distribution of coronary 
disease, compared with the stable cohort (10.3 ± 5.5 vs 7.8 ± 4.4, p=0.02). Labels are not 
shown for the 28 patients with a Syntax score of 5 or 7 to preserve legibility of the plot. 
Overall both patient groups had relatively low SYNAX scores (<22), confirming PCI as a 
suitable mode of revascularisation. The range of values calculated for the NSTEMI cohort 
was higher, with two patients falling into the intermediate group of complexity (SYNTAX 
scores 23-32), whereas all patients in the stable group remained in the low complexity 
category. 
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DNA Ligase Activity, Differential 
Gene Expression and Correlation 
Analyses  
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4.0 DNA LIGASE ASSAY, DIFFERENTIAL GENE EXPRESSION AND 
CORRELATION ANALYSES  
 
4.1 Differential DNA ligase assay in patients recruited to each cohort 
Mean DNA ligase activity was calculated for each cohort excluding samples where nuclear 
protein concentration was too low, as this precluded accurate downstream ligase assays 
(see table 3.1). Measured apparent DNA ligase activity was different across all three groups 
of patients. Data are presented as mean ± standard error mean (SEM). Control samples 
exhibited the highest mean DNA ligase activity (3477 ± 307.9 units per gram of protein) 
followed by NSTEMI (3004.6 ± 377.2) and stable angina (2097.4 ± 238.1). The differential 
ligase activity comparing controls with NSTEMI and stable angina was statistically significant 
(1-way ANOVA p=0.008). Paired post-hoc analysis confirmed the main difference was 
attributed to significantly lower mean DNA ligase activity in the stable angina group 
compared to both other groups. When NSTEMI was compared with the control group, no 
significant difference was observed but there was a trend towards relative lower mean 
apparent ligase activity (see figure 4.1).   
In patients with NSTEMI, DNA ligase activity was measured for the first 12 consecutive 
patients both at the time of PCI and at 30 days post procedure to determine whether 
presentation with NSTEMI, which may be characterized by a systemic inflammatory 
disorder, would cause any differences in attenuated or latent ligase activity. As indicated in 
figure 4.2, there were no differences in DNA ligase activity at the time of presentation or 30 
days post-procedure (1124 ± 168.2 vs. 1217 ± 229.9, p=0.38). Based upon this preliminary 
data, day-30 bloods were not taken for the subsequent NSTEMI patients. It was noted that 
the mean ligase values for this preliminary group were lower than the overall mean values 
obtained for the recruited cohorts by completion of the study. For assessing the mean 
differential DNA ligase activity across all cohorts, repeat analysis of these 12 samples were 
performed and included in calculating the mean apparent ligase activity for each cohort. 
Similar ligase activity levels were obtained for these 12 samples as at the time of 
presentation, removing any doubt of the presence of a significant batch effect. The range of 
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ligase values was highest in the NSTEMI group, with the distribution of data obtained as 
demonstrated in figure 4.3. 
4.1.1 Correlation of DNA ligase activity with atherosclerotic plaque morphology 
Correlation analysis of DNA ligase activity with atherosclerotic plaque anatomy in patients 
with stable angina as measured by FD-OCT indicated a negative correlation between DNA 
ligase activity and lipid arc (Spearman’s rho= -0.37; p=0.03) and DNA ligase activity and 
fibrous cap thickness (Spearman’s rho= -0.4; p=0.03), but no correlation with calcium arc 
(Spearman’s rho= -0.11; p=0.49) (figure 4.4, panels D to F). In patients with NSTEMI, a 
negative correlation was also noted between DNA ligase activity and lipid arc (Spearman’s 
rho= -0.31; p=0.05) and DNA ligase activity and cap thickness (Spearman’s rho= -0.6; 
p<0.0001), but again, no correlation was observed with calcium arc (Spearman’s rho=0.12; 
p=0.46) (figure 4.4, panels A to C).  
In the whole population of patients recruited, there was no correlation between DNA ligase 
activity and the total white cell count (Spearman’s rho=0.11; p=0.24), neutrophil count 
(Spearman’s rho=0.12; p=0.20), lymphocyte count (Spearman’s rho=0.12; p=0.19), 
monocyte count (Spearman’s rho=0.04; p=0.68) (figure 4.5) or the SYNTAX score 
(Spearman’s rho= -0.19; p=0.08) (figure 4.6). These results indicate that differences 
observed in DNA ligase activity are not related to the total white cell count, differential 
white cell breakdown or the extent and complexity of coronary artery disease. 
Importantly, no correlations were observed between DNA ligase activity and age 
(Spearman’s rho= -0.047, p=0.61) which obviates any argument that a non-significant trend 
towards a lower mean control age compared with NSTEMI and stable cohorts may have 
confounded the ligase values obtained (figures 4.7 and 4.8).  
In summary, our data indicates that neither age nor variability in WCC or their differential 
values correlates with DNA ligase activity. More pertinent to the angiographic data would be 
the notion that the complexity of coronary artery disease or presence and degree of 
coronary calcification also bears no correlation with ligase activity. Lipid arc and fibrous cap 
thickness do appear to be correlated, with both forming an inverse correlative relationship 
with apparent DNA ligase activity.  
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Figure 4.1: Differential mean apparent DNA ligase activity between groups of patients 
recruited with mean ± SEM displayed. A significant overall difference was seen with control 
samples having the highest mean DNA ligase activity, followed by NSTEMI and finally stable 
angina cohorts (3477 ± 307.9, 3004.6 ± 377.2, 2097.4 ± 238.1, p=0.008). Post hoc analysis 
revealed a significantly lower ligase activity in the stable angina cohort relative to NSTEMI 
and controls.  
 
Figure 4.2:  Mean apparent DNA ligase activity in patients with non-ST elevation myocardial 
infarction at the time of percutaneous coronary intervention (day 1) and 30 days post 
procedure demonstrating no significant difference (1124 ± 168.2 vs. 1217 ± 229.9, p=0.38). 
Superimposed paired plot demonstrating no definitive direction of change in ligase activity, 
but a trend suggests potential increase over the 30 day period. 
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Figure 4.3:   Univariate scatter plot outlining the distribution of apparent DNA ligase activity 
for each cohort recruited. Red diamonds represent mean values and labels are as previously 
stated. 24 patients with ligase activity less than 1000 u/gram of protein are not labelled.  
Mean ligase activity was significantly lower in the stable angina group (2097.4 ± 238.1) 
compared with NSTEMI (3004.6 ± 377.2) and controls (3477 ± 307.9), with no significant 
difference found between the latter two cohorts.  
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Figure 4.4: Correlations between DNA ligase activity and atherosclerotic plaque characteristics in 
patients recruited to the NSTEMI cohort for [A] mean lipid arc, [B] mean fibrous cap thickness and 
[C] mean calcium arc, and the stable angina cohort for [D] mean lipid arc, [E] mean fibrous cap 
thickness and [F] mean calcium arc. 
 
Figure 4.5: Spearman’s correlation charts demonstrating no significant difference between DNA 
ligase activity and [A] total white cell count, [B] neutrophil count, [C] monocyte count and [D] 
lymphocyte count in all patients recruited to the DECODE study  .
(rho= -0.31, p=0.05) (rho= -0.6, p<0.001) (rho= 0.12, p=0.46) 
  (rho= -0.37, p=0.03)   (rho= -0.4, p=0.03)   (rho= -0.11, p=0.49) 
  (rho= 0.11, p=0.24) 
  (rho= 0.12, p=0.20) 
  (rho= 0.04, p=0.68)   (rho= 0.12, p=0.09) 
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Figure 4.6: Spearman’s correlation chart demonstrating no significant correlation between 
DNA ligase activity with SYNTAX score in all patients recruited to the DECODE study 
undergoing FD-OCT guided PCI for obstructive coronary artery disease (stable angina and 
NSTEMI cohorts). 
 
 
 
 
Figure 4.7: Chart demonstrating no correlation between age of all patients recruited to the 
DECODE study and DNA ligase activity. 
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Figure 4.8:  Scatterplots demonstrating no correlation between DNA ligase activity and age 
in each of the recruited cohorts - [A] NSTEMI, [B] stable angina and [C] controls. 
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4.2 Differential gene expression between cohorts of recruited patients  
To recapitulate, it has been reported that human atherosclerotic plaque VSMCs have 
increased basal DNA damage and enhanced induction of DSBs after oxidative stress, 
associated with increased expression of multiple DDR proteins. Modulating DSBR 
mechanisms have further demonstrated alterations in vitro DDR signalling, cell proliferation 
and apoptosis. Plaque burden has not been shown to be affected by accelerating or 
retarding DSBR in VSMCs, but marked effects on fibrous cap structure have been 
demonstrated. Thus promoting DSBR or attenuating the effects of DNA damage in VSMC 
may exert significant influence on conferring plaque stability. In their study, Gray et al. 
(2015) found the most consistent and differential gene expression between human aortic 
and atherosclerotic plaque VSMCs, focussed around network pathways involving 22 genes 
[28]. Therefore, we selected these 22 genes of interest to examine differential expression 
between PBMCs of patients with and without atherosclerotic coronary artery disease. We 
further examined the relationship between gene expression and plaque characteristics using 
intracoronary imaging in the form of FD-OCT. 
Six samples were excluded on account of failing quality control by having too high a degree 
of genomic DNA contamination for downstream qRT-PCR (see table 3.1). All other samples 
passed the DNA contamination control in addition to RTC and PPC control checks.  
An average expression of all five selected housekeeping genes was measured across all 
samples. This was subsequently subtracted from each housekeeping marker to ascertain if 
and how each expression profile changed in relationship to the average. As figure 4.9 
demonstrates, there was minimal to no change in expression between each housekeeping 
gene relative to the average value across the cohorts, confirming no significant effect of the 
patients underlying disease state on the expression of internal controls. Therefore, the 
reliability of the qPCR data was robust, particularly as 5 internal controls were selected 
compared with 2 or 3 as is the usual protocol with PCR experiments. 
All of the target 22 genes were detected with Ct values less than 35 and when compared 
with controls, there was statistically significant down regulation of those involved in the 
DSBR pathway; XRCC6, RAD50, RBBP8, BRCA1, the NER pathway; XPA and CDK7, as well as 
transcriptional mediators such as SUMO1 and ABL1. Significant up-regulation was noted in 
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OGG1 which is involved in BER; MLH3, a mismatch repair (MMR) enzyme, in addition to 
GADD45A, a p53 target involved in cell cycle arrest and apoptosis (figure 4.10). 
When comparing controls with either stable angina or NSTEMI cohorts in isolation, there 
was significant differential expression observed particularly between stable angina and 
control patients. The up and down regulation mirrored that of the controls versus 
cumulative NSTEMI/stable angina patients demonstrated in figure 4.10, including significant 
down regulation of DDB1, a protein involved in NER and a core component of E3 ubiquitin 
ligase complexes.  
When analysing differential gene expression between NSTEMI and controls, DSBR sensor 
protein RAD50, proto-oncogene ABL1, cell cycle checkpoint protein CDK7, and post 
translational modifier SUMO1 were all down-regulated. OGG1 and MLH3 were both up-
regulated. The genes that were differentially expressed between NSTEMI and controls were 
also up and down regulated in the same fashion as found with stable angina patients 
compared to controls (table 4.1). This suggests that the differences observed in gene 
expression could be attributed to the coronary disease state.    
RT-PCR was performed using the control arm as the baseline condition. When the stable 
angina cohort was compared to NSTEMI, both used the control arm for comparison and 
therefore in order to arrive at values for differential gene expression between NSTEMI and 
stable angina patients, both used controls as a relative comparator. Interestingly, 
statistically significant differential expression was observed, with GADD45A and MLH3 
down-regulated when NSTEMI was compared to stable angina cohorts. Additionally, XRCC6, 
DDB1, RAD50 and BRCA1 were all up-regulated in NSTEMI compared to stable angina 
patients. Hence, the magnitude of up-regulation of GADD45A and MLH3 in NSTEMI 
compared to controls was lower than that obtained in the stable angina cohort versus 
controls. Conversely, the magnitude of down-regulation of XRCC6, DDB1, RAD50 and BRCA1 
obtained from NSTEMI patients compared with controls was less than the degree of down-
regulation observed for these genes in the stable angina cohort versus controls.  
Overall, the relative differential expression between the atherosclerotic coronary cohorts 
and the age and sex-matched controls was low, resulting in small but significant fold 
changes and subsequent fold regulations (figure 4.11). Similarly, despite low fold changes 
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observed when stable angina and NSTEMI groups were directly compared, significant 
differences were attributed due to the magnitude of up and down-regulation of each 
coronary group compared with controls (figure 4.12).  
Table 4.1: Genes differentially expressed between stable angina and NSTEMI patients vs 
controls  
Up-regulated in Stable angina Function of gene encoding protein Up-regulated in NSTEMI 
 
OGG1 (8-Oxoguanine DNA 
glycosylase 1) 
Base excision repair by excision of 8-oxo-
guanine, mutagenic by-product of reactive 
oxygen species exposure 
 
OGG1 
 
GADD45A (Growth arrest and 
DNA damage 45A) 
Activation of ionizing and non-ionizing 
radiation DNA Damage response pathway 
and the G2/M checkpoint 
 
 
MLH3 (MutL Homolog 3) 
Maintenance of genomic integrity during 
DNA replication and meiotic recombination 
 
MLH3 
   
Down-regulated in Stable angina  Down-regulated in NSTEMI 
 
ABL1 (Abelson Murine Leukemia 
Viral Oncogene Homolog 1) 
 
Cell division, cell adhesion, and stress 
response 
 
ABL1 
DDB1 (Damage-specific DNA 
binding protein 1) 
 
Nucleotide excision repair and core 
component of E3 ubiquitin ligase 
complexes 
 
RAD50 
 
DNA double-strand break repair. Forms a 
complex with MRE11A and NBS1 - the MRN 
complex instrumental in DSBR signalling 
RAD50 
XPA (DNA Repair Protein 
Complementing XP-A) 
Interacts with ERCC1, RPA1 and XAB2 to 
mediate DNA damage recognition and 
repair. DNA excision repair 
 
CDK7 (Cyclin dependent kinase 7) 
 
Activates cyclin-associated kinases CDK1, 
CDK2, CDK4 and CDK6 by threonine 
phosphorylation regulating cell cycle 
progression. Component of TFIIH that is 
involved in transcription initiation and DNA 
repair. Nucleotide excision repair 
CDK7 
BRCA1 (Breast cancer 1) 
 
Repair of DNA double-strand breaks, 
ubiquitination and transcriptional 
regulation 
 
RBBP8 (Retinoblastoma-binding 
protein 8) 
 
Regulates cell proliferation and modulates 
the function of BRCA. Involved in DSBR 
 
SUMO1 (Small ubiquitin related 
modifier 1) 
 
Nuclear transport, transcriptional 
regulation, apoptosis and protein stability 
SUMO1 
XRCC6 (X-ray cross 
complementing protein 6) 
Consists of two subunits functioning as a 
single-stranded DNA-dependent ATP-
dependent helicase. Involved in NHEJ 
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Figure 4.9:  Chart demonstrating no significant change in differential housekeeping gene 
expression between cohorts of patients recruited, confirming reliability of internal controls 
for down-stream PCR experiments. Error bars represent the standard error mean. 
ACTB – actin beta; BTM – beta-2-microglobulin; GAPDH - glyceraldehyde-3-phosphate 
dehydrogenase; HPRT1 - hypoxanthine phosphoribosyltransferase 1; RPLP0 – ribosomal 
protein P0. 
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Figure 4.10:  Mean differential expression of genes of interest relative to internal controls for each cohort recruited to the DECODE study. The data is 
expressed as 2^-delta Ct to display the relative expression of each target gene, with the error bars representing SEM and the p value representing 1-way 
ANOVA.  
    n=33            n=48           n=39         
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Figure 4.11:   Volcano plots of differential gene expression of the 22 target genes of interest 
comparing [A] stable angina and [B] NSTEMI versus control cohorts. The x-axis represents 
the fold change. The y-axis is truncated for ease of interpretation. The blue line denotes 
p=0.05. Fold-Change (2^(- Delta Delta Ct)) is calculated as follows: (2^(- Delta Ct)), or the 
normalised gene expression, corrected for internal control, in the test sample (stable angina 
or NSTEMI) divided by the normalised gene expression (2^(- Delta Ct)) in the control sample. 
Fold-regulation represents fold-change results in a biologically meaningful way. Fold-change 
values greater than one indicate a positive- or an up-regulation, and the fold-regulation is 
equal to the fold-change. Fold-change values less than one indicate a negative or down-
regulation, and the fold-regulation is the negative inverse of the fold change.
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Figure 4.12:  Volcano plot of differential gene expression for the 22 genes of interest for 
NSTEMI versus stable angina patients recruited. The blue line represents p=0.05, hence 
above this line represents a statistically significant result. The x-axis represents the fold 
change and the y-axis is truncated for ease of interpretation. 
 
A Z-score normalised (standard score indicating the number of standard deviations from the 
mean) heatmap with dendograms to view co-regulated genes across the groups was 
constructed, using hierarchical clustering of the dataset, with the aid of Dr. Huihai Wu 
(Department of Bioinformatics, University of Surrey). The magnitude of up and down 
regulation is visualised by the number of standard deviations from mean represented by the 
intensity of colour, with red indicating up, and blue, down-regulation (figure 4.13).  
Although the magnitude of differential up and down-regulation is low, the heatmap does 
show that when stable angina patients are compared with controls, CDK7, RAD50, MLH3, 
DDB1, OGG1 and SUMO1 demonstrate the greatest differences in significant expression. 
Although the heat map suggests that gene expression levels in circulating PBMCs from 
patients presenting with stable angina and NSTEMI are relatively similar, the dendrogram 
indicates that DDB1 and MLH3 exhibit differential expression across both coronary cohorts. 
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This aids with presenting the data on an individual patient and gene specific basis, and 
corroborates the relative expression levels plotted in figure 4.10.  
 
4.2.1 Correlations of relative gene expression with atherosclerotic plaque morphology 
Correlation analyses of relative or normalised gene expression of patients presenting with 
stable angina or NSTEMI were performed with FD-OCT derived atherosclerotic plaque 
characteristics. As previously documented, 2^ (- delta Ct) or 2 –delta Ct, was used to represent 
the relative expression of the gene of interest to internal control genes.  
In the stable angina cohort, NLRP2 positively correlated with arc of lipid as displayed in 
figure 4.14 (Spearman’s rho= 0.31, p=0.03). The gene product of NLRP2 interacts with 
components of the IkB kinase (IKK) complex, and can regulate both caspase-1 and NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) activity. The pyrin domain is 
necessary and sufficient for suppression of NF-kB activity, members of which are thought to 
be important in immune responses [171]. No significant correlations were found between 
any of the other target genes with calcium arc, lipid arc or fibrous cap thickness in the stable 
angina group.   
In NSTEMI patients, the relative expression to internal control genes of EBNA1BP2 (r=0.40, 
p=0.02) OGG1 (r=0.50, p=0.003), and DDB1 (r=0.41, p=0.02) positively correlated with 
fibrous cap thickness (figure 4.15). Relative expression of XRCC6 (r= -0.54, p=0.001), XPA (r= 
-0.47, p=0.005), and SUMO1 (r= -0.5, p=0.003) negatively correlated with cap thickness 
(figure 4.16). Conversely, relative expression of OGG1 negatively correlated with calcium arc 
(r= -0.35, p=0.03) (figure 4.17). 
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Figure 4.13:  Heatmap demonstrating relative expression for the 22 genes of interest across all recruited groups of patients. Expression range ‘low-moderate-
high’ is indicated by the colour range and intensity of ‘blue-white-red’ (see colour key at upper left corner), which can be interpreted as down, equivocal or 
up-regulated, respectively. The data provides a method of demonstrating differential expression of the target genes on an individual patient and gene specific 
basis. 
CONTROL STABLE ANGINA NSTEMI 
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Figure 4.14:  Scatterplot demonstrating a positive correlation between relative expression of 
NLRP2 and average arc of lipid in patients presenting with stable angina undergoing FD-OCT 
guided PCI. 
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Figure 4.15:  Graphs demonstrating positive correlations in the NSTEMI cohort between fibrous 
cap thickness and relative expression of [A] EBNA1BP2, [B] OGG1 and [C] DDB1. 
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Figure 4.16: Scatterplots demonstrating negative correlations in the NSTEMI cohort 
between fibrous cap thickness and relative expression of [A] XRCC6, [B] XPA and [C] SUMO1.  
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Figure 4.17:  Negative correlation between average arc of calcium and relative expression of 
OGG1 in patients undergoing FD-OCT guided PCI presenting with NSTEMI. 
 
 
4.3 Future applications: Monocyte isolation, enrichment from fluorescence activated 
cell sorting (FACS) (Collaboration with Dr. Gillian Wallis, University of Surrey) 
Monocytes can be broadly categorised into ‘classical’, ‘non-classical’ or ‘intermediate’. The 
‘classical’ type express high surface levels of the CD14 receptor but is devoid of CD16 
receptors (CD14++/CD-) and represent over 70% of the total circulating monocyte 
population. ‘Non-classical’ monocytes express the CD16 antigen with low or minimal CD14 
expression (CD14+/- /CD16++). The more recently recognised ‘intermediate’ monocyte 
population express both CD14 and to a lesser degree CD16 its surface (CD14++ /CD16+) and 
represent approximately 5% of the monocyte population. Functionally, classical monocytes 
primarily perform phagocytosis giving rise to macrophages and foam cells that ingest native 
LDL, generate reactive oxygen species and secret cytokines in response to 
lipopolysaccharide during inflammation [219]. Non-classical monocytes, in contrast, are 
weak phagocytes and instead demonstrate pro-inflammatory activity by secreting cytokines 
such as TNF-α, interleukin-1b and chemokine (C-C motif) ligand 3 [220]. The intermediate 
subset shares feature of both classical and non-classical sub-types and shows the highest 
spontaneous generation of reactive oxygen species and angiogenesis [221].  
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In order to guide future experiments which may necessitate monocyte enrichment for the 
purpose of down-stream applications such as protein based assays, a preliminary monocyte 
isolation was performed. As our samples were cryopreserved immediately following PBMC 
extraction in -80C, dead cell and cellular debris removal was performed prior to monocyte 
enrichment as described in the methods section. In order to ascertain true enrichment of 
the monocyte population, enrichment of the population expressing both CD14 and CD16 
receptors were analysed, removing any possible confounders such as neutrophil 
polymorphonuclear cells expressing CD16 receptors from the analysis. 
A significant amount of cellular debris persisted from FACS analysis, despite removal with 
the Dead Cell kit and the Miltenyi Monocyte Enrichment kit managed an absolute increase 
of 4.3% of monocytes positive for both CD14 and CD16 receptors on their surface, 
representing a relative 68% increase overall (figure 4.18). Further monocyte enrichments 
were not performed as a research group consensus decision, after consultation with the on-
site Bio-imaging core facility, was reached that the level of enrichment attained and cellular 
debris removed was not significant enough to warrant further resource and time allocation. 
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Figure 4.18: Sample gated strategy demonstrating populations of monocytes based on CD14 and 
CD16 expression in a patient recruited to the DECODE study. Panels [A] and [B] are pre-enriched 
monocytes labelled for CD14 and CD16 monocyte detection, panels [C] and [D] are post –
enrichment. Panels [A] and [C] demonstrate all cells/events recorded based on their size and 
granularity. FSC on the x axis represents Foreware Scatter and measures the laser beam 
penetration around the cell allowing for an estimation of the relative size of the cell. SSC on the 
y axis represents Side Scatter and measures the reflection of laser beam allowing for relative 
granularity of the cell to be calculated.  The P3 gate on this plot (blue/red population) are the 
cells deemed to be viable monocytes and the black population represents non-viable cell 
debris/fragments. Panels [B] and [D] demonstrate fluorescent signal emitted by labelled CD14-
FITC (x-axis) and CD16-PE (y axis). The quadrants Q1,Q2,Q3,Q4 represent; CD14-/CD16+, 
CD14++/CD16+, CD14-/CD16- and CD14+/CD16-, as labelled, respectively. P1 demonstrates 
labelled cells in the pre-enriched population [B] and post-enriched monocyte sample [D] for 
both CD14 and CD16, with a relatively small absolute increase in 4.3%, representing a 68% 
relative increase. 
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4.4 Summary  
Differential gene expression was demonstrated in the PBMC between each of the coronary 
disease cohorts, stable angina and NSTEMI, when compared with the control group with no 
evidence of epicardial coronary artery disease, albeit with relatively small magnitudes of 
fold change. This was found when both coronary groups were compared in isolation with 
the controls, as well as when both groups were compared cumulatively as stable angina and 
NSTEMI together versus the control cohort. Pathways involving multiple DNA repair 
mechanisms were differentially expressed including BRCA1, XRCC6, RAD50, RBBP8 which are 
involved in DSBR; XPA, DDB1 and CDK7 part of NER; OGG1 involved in BER, and MLH3 which 
is important in MMR. In addition, transcriptional mediator SUMO1, proto-oncogene ABL1 
and the G2/M checkpoint enzyme GADD45A integral to cell cycle senescence and apoptosis 
were also differentially expressed. A significant positive correlation was demonstrated 
between EBNA1BP2, OGG1 and DDB1; and a negative correlation between XRCC6, XPA and 
SUMO1 with plaque fibrous cap thickness in the NSTEMI group. OGG1 also negatively 
correlated with calcium arc. In the stable angina group, NLRP2 positively correlated with 
lipid arc. 
Despite no significant difference being found in the atherosclerotic plaque parameters 
between stable angina and NSTEMI patients, a trend towards higher mean lipid arc and 
fibrous cap thickness was found in latter group. Furthermore, most coronary disease 
patients recruited had a low complexity of coronary disease, making PCI a suitable 
treatment strategy rendering them eligible for inclusion for our study.  
Mean apparent DNA ligase activity was significantly higher in the control group, followed by 
the NSTEMI group and lowest in the stable angina cohort. Lipid arc and fibrous cap thickness 
exhibited a negative correlation in both stable angina and NSTEMI groups, however, total 
WCC including its differential breakdown, age and complexity of coronary disease bore no 
relationship with DNA ligase activity. 
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5.0 DISCUSSION 
Accumulated DNA damage and subsequent repair pathways are increasingly recognised as a 
causal factor in the initiation and progression of atherosclerosis [222]. As previously 
mentioned, DDR is reliant on post-translational modification of sensing proteins which 
activate a signalling cascade to repair, if possible, DNA damaged sites in response to various 
environmental and physiological insults. The accumulation of genomic damage as a 
manifestation of genotoxic stressors including environmental toxins and reactive oxygen 
species is classically associated with cancer biology, however, accumulating data over the 
past two decades have implicated the DDR as an essential feature of atherosclerosis [223]. 
Despite this recognition, there is very limited clinical data regarding DNA repair in patients 
with coronary artery disease (CAD) and its correlation with atherosclerotic plaque 
characteristics in humans. 
Animal models have demonstrated repair of DNA strand breaks within weeks of statin 
therapy, but reactive oxygen species-derived formation of mutagenic 8-oxoguanine (8-
oxoG) persisted longer implying inefficient DNA repair in atherosclerosis [224]. 
Apolipoprotein E deficient mice haploinsufficient for the DSBR sensor/transducer ATM have 
been shown to exhibit persistent DNA damage and a failure to repair DNA, which as a 
consequence was postulated to lead to mitochondrial dysfunction, apoptosis and defects in 
cell proliferation [84]. PBMCs isolated from patients with stable angina and acute coronary 
syndrome were shown to exhibit mitochondrial DNA damage and shortening of telomeres 
as evidence of overt DNA damage. In the first human study of its kind, monocytes isolated 
from these recruited patients had elevated basal and lipopolysaccharide induced monocyte 
chemoattractant protein-1, interleukin-6 and interleukin-1β cytokine release [225]. This, 
along with increased reactive oxygen species production suggests that DNA damage may 
play a key role in the formation of a pro-inflammatory monocyte/macrophage phenotype. 
Furthermore, induced DNA damage using telomere-disrupting agent telomestatin 
reproduced this phenotype [155]. Both mitochondrial DNA damage and telomere 
shortening were correlated with thin-capped fibroatheroma indicating that peripheral 
circulating cells may serve as robust markers of atherosclerotic plaque anatomy. Further 
support for this premise is offered from studies using peripheral lymphocytes from patients 
with CAD, which have also been shown to exhibit a higher micronucleus index than healthy 
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controls as well as increased DNA strand breaks, oxidized pyrimidines and altered purines 
[36,80]. Additionally, human plaques exhibit up-regulation of DNA repair enzymes such 
PARP-1, DNA-dependent protein kinase and XRCC1 in association with markers of DNA 
damage [225]. Finally, cultured plaque VSMCs show enhanced double-strand break 
formation both at baseline and following exposure to oxidative stress indicating that DSBR 
may be defective within the plaque microenvironment [226]. 
DNA ligase, which facilitates the joining of DNA strands by catalysing the formation of a 
phosphodiester bond between 3' hydroxyl ends of one nucleotide, with the 5' phosphate 
end of another, plays a key role in single-strand break repair as well as in DSBR. It was 
consequently used as a marker of DNA repair activity in the cohorts of patients recruited 
and is recognised in playing a key role in maintaining efficient DNA replication. 
The novel microplate assay developed for DNA ligase activity measured a combination of 
ligase I, III and IV activity in nuclear extracts prepared from PBMCs from patients with 
NSTEMI, stable angina and healthy controls. Furthermore, by using PBMCs to measure BER 
and DSBR, pertinent repair pathways in response to oxidative stress, we demonstrated that 
patients with CAD had a lower DNA ligase activity than age and sex matched controls and 
discovered the presence of a negative correlation between DNA ligase activity, lipid arc and 
fibrous cap thickness as measured by FD-OCT.   
When comparing overall DNA ligase activity in patients with CAD versus controls with no 
angiographic evidence of epicardial atherosclerosis, we demonstrated lower ligase activity 
in both stable angina and NSTEMI groups. Lowest mean activity was recorded in the stable 
angina cohort, followed by NSTEMI, suggesting that patients with a chronic atherosclerotic 
state may have lower innate DNA ligase utilising repair activity, or that a chronic 
atherosclerotic process attenuates overall DNA ligase activity compared to the acute 
unstable atherosclerotic plaque. To distinguish between these hypotheses would warrant 
further measurements of concurrent markers of specific DNA damage along with a 
correlative assay of DNA ligase activity and serial measurements over a longer time period, 
all of which were beyond the scope of our study. It must be remembered, however, that 
post-hoc paired analysis demonstrated no significant difference between DNA ligase activity 
in NSTEMI compared with age and sex-matched control cohorts. Pathophysiologically, stable 
angina and the higher risk NSTEMI represent two distinct manifestations of CAD as 
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mentioned earlier. Presentations of NSTEMI occur when the ischaemia is sufficiently severe 
to cause myocardial damage that results in the release of a cardio-specific biomarker of 
myocardial necrosis into the circulation. Stable angina conversely does not typically result in 
the release of myocardial necrosis biomarkers and does not usually cause permanent 
myocardial damage.  The pathogenesis of acute coronary syndromes such as in NSTEMI 
therefore involves a complex interplay between inflammatory cell recruitment and 
subsequent cytokine release, endothelium and the thrombogenicity of blood [227]. 
Angiographically non-critical coronary lesions may therefore be associated with abrupt 
progression towards severe or total occlusion.  Factors such as the lipid and tissue factor 
content of the plaque, the severity of the plaque rupture, the degree of inflammation at the 
site, the blood flow in the area, and the patient's antithrombotic and prothrombotic balance 
have previously been shown to be important in controlling the degree of thrombus 
formation and determining whether a given plaque rupture will result in an acute coronary 
event [228].  
In the sample population of patients with stable angina and NSTEMI, a negative correlation 
between DNA ligase activity and both the lipid arc, a surrogate for the lipid core, and fibrous 
cap thickness was also found. The three main cellular components of the atherosclerotic 
plaque are VSMCs and lymphocytes, which dominate the fibrous cap, and macrophages, 
which are most abundant in the lipid core.  Apoptosis, which occurs in response to 
irreparable DNA damage, has been previously observed in all the major plaque cell 
components and has been proposed to promote plaque instability [229]. In VSMCs, 
increased levels of apoptosis are seen in advanced lesions as well as in unstable plaques 
which may contribute to fibrous cap thinning and plaque rupture.  
The contribution of plaque VSMC apoptosis to plaque vulnerability has been further 
demonstrated in an Apo-E null mouse model, using an SM22α-human diphtheria toxin 
receptor where selective induction of VSMC death was shown to lead to thinning of the 
fibrous cap, loss of collagen, accumulation of cellular debris, and elevated levels of IL-6 
[230]. Similarly, apoptotic macrophages localise to the plaque core and sites of plaque 
rupture indicating that macrophage death may promote plaque instability [231]. In mouse 
models of macrophage apoptosis, it has been demonstrated that apoptosis in early foam 
cell lesions limit lesion cellularity and progression due to efficient phagocytosis and 
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phagocytic clearance [232-234]. However, as atherosclerotic lesions progress, increased 
levels of apoptotic macrophages lead to elevated levels of inflammatory markers such as 
TNF-α, secretion of matrix-degrading proteases and promotion of plaque instability [232]. In 
addition, elevated levels of ROS occurs with inflammation, a known risk factor for 
accelerated CAD, which increases the likelihood of DNA damage and reiterates the 
importance of assessing DNA repair markers in order to ascertain if this is altered in 
atherosclerosis. 
Although DNA ligase activity may have been reduced in CAD, the most vulnerable plaques 
observed as those with thinner fibrous caps overlying lipid pools correlated with a higher 
ligase activity. One could postulate that a higher ligase activity occurs in response to higher 
risk atherosclerotic plaque formation, as observed by higher ligase activity in NSTEMI 
compared with stable angina groups. However, revascularisation of the culprit lesion in 
NSTEMI did not result in an attenuation of DNA ligase activity 30 days following. Indeed, 
there was a statistically non-significant trend towards an increase in DNA ligase activity at 
the 30 day repeat assay suggesting that either ligase activity does not increase or decrease 
in response to the degree of underlying atherosclerotic exposure, or, that 30 days is too 
short a time to assess any consequential attenuation of ligase activity after the index 
revascularisation procedure. It is interesting given that one would expect a higher level of 
DNA repair and replicative activity to be associated with a thicker protective fibrous cap and 
therefore a more stable atherosclerotic state. Conversely, our findings suggest although a 
chronic atherosclerotic state is associated with lower DNA ligase activity compared to an 
acute higher risk state (stable angina versus NSTEMI groups), higher risk subsets within each 
cohort, as represented by a thinner fibrous cap, appears to be associated with a higher DNA 
ligase assay. This may be partially explained by the paradigm of an imbalance in BER, where 
an increase in base excision repair activity may be associated with an increase in DNA 
damage-induced tissue injury. As DNA ligase activity is part of a multi-step pathway, where 
one enzymatic step leads to the formation of intermediates in the DNA repair pathway, an 
imbalance can lead to poor coordination of the process, risking defective DNA repair, 
despite markers such as ligase activity remaining high. An adaptive increase in BER enzymes 
have been associated with microsatellite instability in chronic inflammatory conditions such 
as ulcerative colitis [235] and in visceral ischaemic reperfusion injury [236]. 
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The negative correlation demonstrated between DNA ligase activity and arc of lipid suggests 
that a higher substrate for the formation of a necrotic core exists with diminishing levels of 
ligase activity. With lower levels of DNA ligase activity potentially contributing to reduced 
BER and DSBR repair, increased cellular apoptosis may result in a larger lipid pool and 
subsequent necrotic core promoting higher atherosclerotic plaque vulnerability, concurring 
with previously published data [232,233]. Combining both the fibrous cap and lipid 
correlation data may suggest that in patients with a lower measured DNA ligase activity, a 
larger lipid arc and hence necrotic core co-exists with a thicker fibrous cap, which may be 
protective in avoiding a MACE associated high risk thin-capped fibro-atheromatous 
phenotype. In patients with a higher DNA ligase level of activity, the converse is postulated.  
Again, the imbalanced BER paradigm may be invoked as a possible mechanism for explaining 
the combination of these findings. 
Age, variability in total and differential white cell counts were reassuringly shown to not 
influence the level of DNA ligase activity. The complexity of coronary artery disease, as 
measured using the SYNTAX score, also did not demonstrate any significant correlation with 
DNA ligase activity suggesting that these factors were not confounders in the results 
obtained. The burden of atherosclerosis therefore may not directly influence the level of 
DNA ligase activity, whereas atherosclerotic plaque characteristics that render a higher 
degree of vulnerability may play a key role. 
In addition to lower levels of DNA ligase activity in CAD cohorts, down-regulation of a 
number of genes involved directly and indirectly with DSBR was observed in both stable 
angina and NSTEMI patients. We found that all genes that were differentially expressed 
from our 22 gene analysis exhibited complete concordance with the direction of up/down 
regulation as that of Gray et al. (2015). In their experiment, cultured plaque VSMCs were 
used for down-stream gene analysis, suggesting that PBMCs isolated from peripheral blood 
may be an effective surrogate for atherosclerotic plaque tissue [28]. We do accept, 
however, that our data indicates the level of fold changes obtained with PBMCs for the 
genes of interest are significantly lower than those obtained with cultured VSMC.   
In particular, down-regulation of XRCC6, RAD50, RBBP8 and BRCA1 were observed in stable 
angina patients compared with controls. XRCC6 encodes the Ku70 protein which forms a 
heterodimer with Ku80 and is required for NHEJ in addition to maintenance of telomere 
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length. RAD50 forms the MRN complex with MRE11 and NBS1, and is involved in numerous 
enzymatic stages of DSBR in both NHEJ as well as homologous recombination. RBBP8 is an 
endonuclease that functions along with the MRN complex in DNA-end resection, the initial 
stage of DSBR through homologous recombination.  BRCA1 is a tumour suppressor gene and 
plays an important role in error-free DSBR, preventing mutagenic replication. CDK7, which 
encodes cell division protein kinase7, which in turn forms a trimeric complex forming an 
essential component of the transcription factor TFIIH involved in initiating NER, was down-
regulated in both stable angina and NSTEMI compared with controls.  
Additionally, NER protein XPA and transcriptional mediators SUMO1 and ABL1 were also 
down-regulated in the stable angina cohort.  SUMO1 is a protein family member involved in 
post-translational modification resulting in a variety of cellular processes such as 
transcriptional regulation, apoptosis and protein stability. It helps to regulate calcium 
homeostasis in myocardial mitochondrial cells and interacts with sarco/endoplasmic 
reticulum Ca2+, ATPase or SERCA2A. By activating and binding at lysine residues 480 and 585, 
SUMO1 stabilises SERCA2A in managing intracellular calcium homeostasis and subsequent 
myocardial contractility [237,238]. SUMO1-dependent modulation of SERCA2A has been 
proposed in heart failure [239], however, SUMO1 expression in patients with CAD and its 
effects on atherosclerotic plaque as demonstrated in our study, had thus far been unknown.  
Despite reduced activity of DNA ligase and a number of genes involved in the DNA repair 
pathways, there was also increased expression of genes involved in BER such as OGG1, 
MMR repair such as MLH3, and p53 targets such as GADD45A. Although the role of MLH3 in 
atherosclerosis has not been previously studied, OGG1 has been shown to play a protective 
role in atherosclerosis [240]. As demonstrated in figure 5.1, the network of genes analysed 
exhibit a complex interplay in the maintenance of DNA damage and repair in atherosclerosis 
in patients with obstructive coronary artery disease in stable angina. 
As previously stated, when comparing the NSTEMI group in isolation against the control 
group, although fewer genes were affected, the pattern of significant up and down-
regulation was the same as those in the stable group (down-regulated: ABL1, RAD50, CDK7, 
SUMO1; up-regulated: MLH3, OGG1). This suggests that the coronary disease state 
influences over or under expression of this set of genes relative to internal controls. The 
magnitude of up and down regulation was lower in the NSTEMI group compared with the 
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stable group, which may suggest a higher level of relative over or under expression in 
chronic coronary cohorts. 
 
 
 
Figure 5.1:  Pathway analysis of DNA damage response and repair pathways statistically 
significantly (p < 0.05) up and down-regulated in the stable angina cohort undergoing FD-
OCT guided PCI (n=48) when compared with controls (n=33).  
 
In patients with NSTEMI, our data indicated that low expression of OGG1, DDB1 and 
EBNA1BP2 correlated with thinner fibrous caps. These findings are supported by animal and 
in-vitro studies examining the effects of OGG1 and DDB1 [240,241]. Tumurkhuu et al. (2016) 
demonstrated the protective effect of OGG1 against atherosclerosis as illustrated in their 
study in which OGG1(-/-)Ldlr(-/-) mice that were fed a Western diet developed increased 
plaque size and lipid content. The plaques contained increased oxidized mitochondrial DNA, 
inflammasome activation and apoptosis whilst there were elevations in serum IL-1ß, and IL-
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18. OGG1 levels were found to be lower in the macrophages of atherosclerosis and 
macrophages lacking OGG1 were more sensitive to oxidant stress and subsequent 
apoptosis. Restoration of OGG1 status protected against these changes as well as reducing 
plaque size [240]. This suggests that up-regulation of OGG1 in a higher risk CAD cohort, such 
as patients presenting with an acute coronary event, confers a thicker fibrous cap and 
therefore a more stable atherosclerotic plaque protected from rupture. More recently, it 
was demonstrated that defective 8-oxoG BER was associated with decreased expression and 
acetylation of OGG1 protein, with effective OGG1 activity controlled by Lys338/Lys341 
acetylation in human plaque VSMCs. Although OGG1 mRNA was increased in human plaque 
VSMCs, as found by up-regulation in our stable and NSTEMI cohorts when compared with 
controls, acetylated OGG1 and OGG1 protein expression was reduced suggesting post-
translational mechanisms playing a key role in controlling activity. p300 and SIRT1 were 
identified as major acetyltransferase and deacetylase enzymes directly targeting OGG1, and 
thus regulating 8-oxoG BER and 8-oxoG content in VSMCs. p300 expression was reduced in 
plaque VSMCs and by oxidative stress, and subsequent reduced formation of the p300-
OGG1 complex compromised OGG1 activity and protein stability. Inhibition of endogenous 
oxidative damage by rescuing VSMC OGG1 reduced atherosclerotic burden in-vivo, a process 
which appears to require OGG1 acetylation. Chronic oxidative stress in atherosclerosis 
resulted in down-regulation of p300 dependent acetylation of OGG1, resulting in reduced 
OGG1 protein stability and hence overall 8-oxoG repair activity [242]. 
EBNA1BP2 or EBNA binding protein 2 is responsible for encoding probable ribosomal-RNA-
processing protein EBP2 and is involved in large unit ribosomal biogenesis [174]. Thus far 
there has been no association reported between its expression and effects on 
atherosclerotic CAD, but our data suggests an atherosclerotic protective effect against 
plaque rupture associated with higher expression. 
DDB1 has been shown to interact with the promoter of fibromodulin and is responsible for 
its activation following ultraviolet light exposure. Fibromodulin is a small, leucine-rich repeat 
protein that is involved in the assembly of the extracellular matrix. It has been hypothesised 
that the ultraviolet light-induced fibromodulin increase is a mechanism that counteracts 
connective tissue damage or a remodelling process involving the synthesis of new matrix 
proteins [241]. Further support of its protective effect is demonstrated in Zebrafish 
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embryos, whereby disruption of DDB1 activity resulted in a degenerative phenotype with 
reduced organogenesis including brain and skeletal development in the larval stages. Thus 
DDB1 was shown to be instrumental in maintaining proper cell cycle progression and 
viability of dividing cells during development through transcriptional mechanisms regulating 
genes involved in cell cycle control and cell survival [243]. Our study suggests that a higher 
expression of DDB1 ensures appropriate cell cycle progression and by activating 
fibromodulin, may prevent excessive connective tissue damage and subsequent negative 
remodelling along with apoptotic processes that contribute to a more vulnerable plaque. 
This may also help to explain, therefore, a lower expression in patients with obstructive 
atherosclerotic CAD in the stable angina cohort.  
In contrast, we observed that low expression of SUMO1, XRCC6, and XPA correlated with 
thicker fibrous caps. Although the roles of XRCC6 and XPA in human atherosclerosis have 
not yet been elucidated, our finding regarding SUMO1 is consistent with previously 
published studies. The SUMOylation of proteins, including p53 and extracellular-signal-
regulated kinase 5 (ERK5), under conditions of disturbed flow have been shown to 
contribute to plaque formation [244], whilst ERK5 SUMOylation was increased in the vessels 
of diabetic mice and may contribute to endothelial dysfunction [245]. SUMO1 has also been 
shown to inhibit the activity of NADP oxidases 1 to 5 and thus inhibit the generation of 
reactive oxygen species in cultured VSMCs, neutrophils as well as human embryonic kidney-
NOX5 cells suggesting that a decrease in the expression of SUMO1 may have protective 
properties in the plaque microenvironment [246], concurring with findings from our study 
related to plaque vulnerability. It is interesting, however, that SUMO1 expression was down-
regulated in both the stable angina and NSTEMI groups compared with controls, which does 
contradict some of the earlier literature regarding its role in atherosclerotic process 
[244,245].  
NLRP2 (NACHT, LRR and PYD domains-containing protein 2) was found to positively 
correlate with arc of lipid in the recruited stable angina cohort. It suppresses tumour 
necrosis factor (TNF) and CD40-induced NF-kB1 activity at the level of the IKK complex, by 
inhibiting NF-kBIA degradation induced by TNF. When associated with PYCARD, or ASC 
(Apoptosis-associated speck-like protein containing a CARD) caspase-1 is activated, leading 
to the secretion of mature pro-inflammatory cytokine IL1B [247]. Although there has been 
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significant association reported in the literature between NLRP3 inflammasome activation 
and atherosclerosis [248,249], there is little documented with respect to NLRP2. Szpakowicz 
et al. (2015) demonstrated an association between NLRP2 and patients with rs12526453 
(C/G) single nucleotide polymorphism (SNP) in an intron of the PHACTR1 gene (phosphatase 
and actin regulator 1) [250]. The C allele has previously been shown to be associated with an 
increased risk of coronary artery disease via an unknown mechanism [251]. CC homozygotes 
for the SNP rs12526453 demonstrated better long term survival when presenting with and 
treated invasively for ST-elevation MI. Transcriptomic analysis revealed a significantly higher 
expression of NLRP2 in these CC homozygotes, suggesting its function as an inflammatory 
process modulator may be used in an intermediating process in the effect of the SNP on 
long term prognosis following ST-elevation MI. It may also paradoxically explain why the C 
allele, which increases the risk of CAD and MI, confers protection once MI has occurred. 
Although a direct mechanism by the increase in lipid arc cannot be explained, one can 
hypothesise that its pro-inflammatory activation may lead to an enhanced inflammatory 
state leading to cellular death and an increased lipid-rich necrotic core.   
Statin use varied between the cohorts, with the vast majority of patients either taking or 
initiated on some form of statin therapy in the coronary disease cohorts. As would be 
expected, the control patients had a relatively lower statin use. The study did not assess the 
specific effects of statin use on the DDR and its effects on DNA repair mechanisms, however, 
several studies have demonstrated its effect on inhibiting cell senescence, accelerating DNA 
repair, telomere shortening and reducing overall chromosomal damage. Plaque progression 
is altered by reducing levels of oxidized LDL and subsequent oxidative DNA damage within 
vessels. They have been shown to help preserve endothelial function by inhibiting pathways 
involved in the post-translational modification of GTPases Rho and Rac, which are important 
in nitric oxide and NAD(P)H oxidase-dependent superoxide radical formation [252,253]. 
Certain statins have been shown to reduce superoxide formation by direct free radical 
scavenging independent of lipid metabolism [254-257]. In particular, a reduction in 
cytotoxicity-induced oxidative damage has been observed with atorvastatin [258]. 
Mahmoudi et al. (2008) also identified a mechanism by which atorvastatin provided 
protection against DSB in irradiated VSMC. Accelerated DNA repair was dependent on NBS1 
stabilisation, phosphorylation of human double minute protein 2 (Hdm2), dissociation of 
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NBS1 and Hdm2, inhibition of NBS1 degradation and more rapid ATM phosphorylation 
[154]. Moreover, lovustatin was found to increase mRNA expression of a subset of repair 
genes in vivo [259], as well as block ionising radiation-induced prototypical DNA damage 
responses such as the increase in p53 protein level and ATM/ATR-regulated activation of 
Chk1 in primary human endothelial cells [260]. These findings concurred with studies 
demonstrating the DNA damage-mitigating properties of simvastatin therapy in 
dyslipidaemic diabetic [261] and end stage renal failure patients [262]. By delaying 
senescence, telomere shortening and enhancing DNA repair, particularly in VSMC, the 
literature suggests that the radio-protective pleiotropic effect of statins may confer a 
reduction in atherosclerotic plaque formation as well as promote plaque stability. 
We have identified previously unreported differential expression of genes involved in DDR 
between stable and unstable presentations of atherosclerotic CAD in vivo, as well as 
correlations between DNA repair assays using DNA ligase activity and plaque morphology in 
such cohorts. Based upon this data, we speculate that a reduction in DNA ligase activity in 
higher risk coronary groups has an association, and may play an important contributing 
factor in the development of the atherosclerotic lipid rich necrotic core. Conversely, 
increased expression of genes such as OGG1 and DDB1 or down-regulation of genes such as 
SUMO1 and XPA may contribute to increased fibrous cap size, conferring atherosclerotic 
plaque stabilisation.  
By reporting the differential activation of multiple DNA repair pathways, morphological 
plaque correlations and DNA damage signalling mechanisms; we have demonstrated the 
complex genomic interactions involved in atherosclerotic plaque formation and stability in 
different presentations of CAD in humans. 
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5.1 Limitations and future directions 
Despite our novel data, DNA ligase activity was measured in PBMCs rather than individual 
cellular components, in particular peripheral monocytes. Although this may have been more 
informative, lymphocytes, monocytes and neutrophil activity are implicated in the 
atherosclerotic process [7]. In view of this, a trial assay of monocyte isolation and 
enrichment was performed for the purposes of down-stream applications, however, the 
level of enrichment attained was deemed too low for further time and resource allocation. 
Further isolation and culture of such cells in a large cohort of patients may have been 
extremely challenging within the confines of the resources available for this study. There 
was no significant correlation found between the differential white cell counts and DNA 
ligase activity, but it would be interesting to perform such assays from further enhanced 
monocyte samples for completeness. 
Additionally, our gene analysis was limited to a group of 22 genes that was previously shown 
to be the most robust panel involved in atherosclerosis [28], rather than all the recognised 
genes in the DDR and DNA repair pathway. By extending our experiments to incorporate a 
broader panel of genes and markers, more extensive analysis could provide further insights 
into the alterations that occur in differing presentations of atherosclerotic CAD. 
As our patient cohort had a low SYNTAX score, representing a sample set of patients with a 
lower complexity of CAD, we cannot be certain that our findings can be extrapolated to 
those with intermediate and high SYNTAX scores. However, it is possible that such patients 
may exhibit a more profound alteration in DNA ligase activity and genes involved in the 
DDR. Patients with the highest SYNTAX scores would by definition have the most complex 
CAD and may have been unsuitable for recruitment as revascularization may not have been 
appropriate percutaneously.  
Statins have been shown to influence DDR and DNA repair in VSMC. Although our study did 
not adjust for the specific effects of statin use on gene expression in DDR and DNA repair in 
recruited cohorts, further work could expand our analyses incorporating the duration and 
dosage of various statins on differential gene expression between groups, in addition to 
correlations with atherosclerotic plaque parameters.   
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Our study also did not adjust for the specific effects of smoking on DNA damage and repair 
and their subsequent effects on coronary atherosclerosis. As it is recognised as a significant 
independent risk factor for CAD, it was felt that excluding patients based on smoking history 
would jeopardise recruitment and completion of the study based on our catchment area. 
The association between smoking and DSBs has been previously demonstrated both in vitro 
[263,264] and in vivo [265]. Several genome wide association analyses have demonstrated 
epigenetic modifications in smokers with particular attention to differential methylation of 
CpG sites (short-hand notation for regions of DNA where a cytosine nucleotide is followed 
by a guanine nucleotide in the linear sequence of bases along its 5' → 3' direction) [266-
268]. Results from the KAROLA prospective cohort study seem to indicate a lower 
methylation level in F2RL3 (F2R-like thrombin or trypsin receptor 3) to be a potential 
mediator of the detrimental impact of smoking and to be strongly related to mortality 
among patients with stable coronary artery disease [269]. Effects on cardiovascular 
mortality are unsurprising given that F2RL3 encodes protease-activated receptor 4 (PAR-4), 
also known as coagulation factor II (thrombin) receptor-like 3, which is involved in vascular 
processes such as platelet activation, intimal hyperplasia, and inflammation [270]. Indeed, a 
small study demonstrated that smoking induced DSBs from examined peripheral 
mononuclear cells and was reversed with smoking cessation for one month. By measuring 
the cytologically visible foci using an antibody to γ-H2AX, young healthy smokers were found 
to have significantly higher γ-H2AX foci when compared with healthy non-smokers [265]. A 
comprehensive meta-analysis of genome wide blood-derived DNA methylation identified 
broad epigenome-wide impact of cigarette smoking. In total, 18,760 statistically significant 
CpGs annotated to over 7,000 genes, which in turn affected multiple molecular mechanisms 
and were implicated in smoking-related phenotypes and diseases. It corroborated previous 
findings from smaller studies [271] as well as detecting over 16,000 novel differentially 
methylated CpGs in response to cigarette smoking [272]. Expanding our findings to 
incorporate differential gene analysis on patients with CAD with and without a smoking 
history may aid in identifying the specific effects of smoking on DDR and repair in 
atherogenesis. This may help in further risk stratifying smokers most at risk from vulnerable 
plaques based on their gene profile.   
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Patients that were recruited to the control arm underwent coronary angiography with no 
evidence of epicardial coronary atherosclerosis. These patients would have been referred 
for invasive coronary angiography based on clinical judgement of symptoms and or non-
invasive myocardial perfusion imaging. Although no epicardial atherosclerosis was evident 
angiographically, it does not exclude the presence of microvascular dysfunction causing 
angina in recruited controls.  Its pathological mechanisms are thought to be related to 
epicardial coronary spasm, coronary bridging, coronary slow-flow phenomenon, Takotsubo 
cardiomyopathy or stress related cardiomyopathy and coronary microvascular dysfunction 
[273].  
The coronary microcirculation is not usually the subject of routine imaging however, its 
dysfunction is thought to compromise myocardial perfusion as it is the major determinant of 
vascular resistance, accounting for over 80% of total resistance. Hence, the coronary pre-
arterioles and arterioles measuring less than 500 μm in diameter physiologically modulate 
coronary blood flow, in response to neural, mechanical and metabolic factors [274,275]. 
Conventional cardiovascular risk factors such as hypertension and diabetes are implicated as 
predisposing to dysfunctional microvasculature, although it is worth noting that diabetics 
were excluded from our study [276]. Impaired vasodilatation capacity accompanied in some 
subjects with enhanced vasoconstrictor tone increase coronary blood flow resistance, 
reduce coronary flow reserve and may precipitate myocardial ischemia without affecting 
the epicardial coronary vessels visualised with invasive coronary angiography [277]. 
Endothelium dependent mechanisms reliant on nitric oxide release, and independent 
mechanisms determining smooth muscle relaxation, can be revealed by the failure of 
coronary blood flow to increase in response to coronary vasodilators such as acetylcholine 
or dypridamole [278,279].  
Evaluation of microvascular function include assessing vascular flow responses to these 
vasodilator stimuli and calculating the coronary flow reserve (CFR) as the ratio between 
hyperaemic and basal coronary flow. A CFR below 2.5 is generally considered as diagnostic 
of microvascular disease during invasive angiography, which would aid with excluding 
epicardial disease and vasospasm [274]. To elaborate, it is possible to assess microvascular 
function through several techniques: thermodilution or gas washout method and 
intracoronary doppler flow wire allow coronary blood flow and CFR quantification. 
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Intracoronary doppler is the most commonly used as it allows direct measurement of 
coronary blood flow (CBF) velocity in single epicardial arteries. The product of CBF velocity 
and the cross-sectional arterial area gives a measure of CBF. Evaluations prior and post 
vasodilator infusion allows the CFR measurement. By incorporating data from intracoronary 
doppler and pressure sensor assessment, it is possible to calculate the index of 
microvascular resistance (IMR), defined as the distal coronary pressure multiplied by the 
hyperaemic mean transit time.  
Invasive assessment of microvascular angina is not routinely performed as part of coronary 
angiography. It would require further resources, training and equipment with minimal 
benefit and change in patient management. Consequently, it did not form part of our 
protocol and was not performed on patients recruited to the control cohort. Potential 
expansion of our work may incorporate microvascular assessment in patients without 
epicardial coronary disease. However, this would require an in-depth analysis of the cost 
versus benefit of recruiting such patients to a translational study, in addition to resourcing 
the availability of specialised training and equipment. 
We recognise this study does not provide a mechanism by which alterations in the DDR 
contribute to atherogenesis but merely describes the alterations that occur in these 
biological systems. We also accept that despite finding significant correlations between DNA 
ligase activity and genes expressed in the DDR, with atherosclerotic plaque features; our 
study demonstrates an association rather than outlining the definitive cause and effect of 
differential gene expression and ligase activity between patients with and without coronary 
atherosclerosis. 
It would be useful to assay markers of DNA damage such as phosphorylated histone 2AX or 
γ-H2AX, a robust marker of DSB in conjunction with markers of DSB repair such as DNA 
ligase to see whether a reduced ligase activity indeed correlates and or corresponds with 
elevated markers of DSB. This in turn could be correlated with atherosclerotic plaque 
features to ascertain if and how specific DNA damage markers and subsequent repair 
activity contribute to the atherosclerotic process. 
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Appendix A – Configuration of 384-well plate using a 32 gene by 12 sample 
arrangement 
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Appendix B – Patient Information Sheet 
 
Patient Information Sheet  
 
DNA DamagE and Repair in Atherosclerotic COronary Artery DiseasE  
(The DECODE Study) 
 
Responsible Doctor: Dr. Michael Mahmoudi 
Sponsor: Ashford & St. Peter’s Hospital NHS Foundation Trust 
Version 5: May 20th, 2015 
 
Invitation 
You are being invited to take part in a research project and this Information Sheet explains what will 
happen if you agree.  Before you make a decision, you should understand why the research is being 
done and what it would involve for you. One of our team will go through the information sheet with 
you and answer any questions you may have. This may take 10 minutes. 
Please ask if anything is not clear, and feel free to talk to your family and friends about the study if 
you wish, before making your decision. 
The development and progression of coronary artery disease are highly variable and driven by both 
genetic and environmental factors. In collaboration with the University of Surrey, we are currently 
examining some of the potential reasons why some individuals develop angina whilst others present 
with a heart attack. Angina, or chest pain due to inadequate blood supply to the heart muscle, 
develops over a number of years and is due to narrowing of one or more of the coronary arteries as a 
result of cholesterol deposition in the wall of these arteries. A heart attack is when there is sudden, 
partial blockage in one of the major arteries that take blood to the heart muscle leading to the death of 
heart cells. If we can understand some of the reasons why this happens, it may be possible to develop 
specific treatment strategies that could prevent the development of angina or a heart attack. 
What is the Purpose of the Research 
We have previously identified a number of proteins whose levels are raised in the coronary arteries of 
individuals with angina and heart attacks. The purpose of this study is to determine firstly if such 
proteins can be detected in blood and secondly if we can identify individuals who are at high risk of 
developing a heart attack through such a blood test before they develop their conditions.  
Examples of high-risk individuals include those with angina, high blood pressure, diabetes mellitus 
(high blood sugar level) as well as those who smoke cigarettes.  
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Why Have I Been Invited 
Your Cardiologist has recommended that you should have a coronary angiogram (take pictures of the 
blood supply to your heart) to look whether you have any narrowing in the blood supply to your heart 
and, if suitable, to have these narrowing treated with stents (metal scaffolds that stretch narrowed 
arteries and keep them open). This may be because you have angina or have been admitted to hospital 
with a heart attack. 
Do I Have to Take Part 
No.  It is entirely your decision whether or not you wish to participate. Your decision will have no 
impact on your treatment.  
What Would Participation Involve 
Participation in this study does not affect the treatment that you will be receiving for your heart 
condition. Participation in this study would require you to give a blood sample (40 to 50 ml, about 8 
teaspoons) in addition to the other routine blood tests that will be required as part of your treatment. 
This blood sample will be then transferred to the University of Surrey where the white cells from your 
blood will be taken and stored, anonymously, in a large, locked freezer. All direct links to your 
identity will be removed from the sample before it is stored. Your sample will then be used to analyse 
the levels of proteins involved in detection and repair of DNA in the white cells. These tests are aimed 
at helping us understand why some people develop angina and some people develop heart attacks 
when compared with people without narrowings in their coronary arteries. 
Once you have been discharged from the hospital, we will require you to be contacted for potentially 
two additional visits. The first visit will be 1 month after your discharge from the hospital, if you have 
been allocated to the heart attack group, and this is for you to give another blood sample (40 - 50 ml, 
about 8 teaspoons). This visit will take approximately 5 minutes.  The second contact will be either a 
follow-up visit or a phone call and will be 12 months after your discharge from hospital. The purpose 
of this would be for a general check-up. This visit will take approximately 15 minutes.  
How Will My Identity & Results Be Kept Confidential? 
Your blood sample will be stored at the University of Surrey. When your sample is stored, it will be 
given a code number that will allow the sample to be linked to information such a sex, blood pressure, 
smoking habit, diabetes, and kidney function. We will have a link to the blood through a linked 
anonymised database and will not contact any participant with any result. If an important result is 
derived from this research, it will be shared with the public and the medical community. 
Who May See My Results? 
Your results will be available to the principle investigator for the study (Professor Michael 
Mahmoudi) and his research student (Dr. Nikunj Shah). However, when results are being analysed, 
this will be done using a set of information with all your personal information removed. Security 
measures such as passwords for databases and controlled access to buildings will ensure that data and 
samples are securely stored. Your information will only be used for the purposes of research. Your 
results will not be given to employers, insurance companies or the public. You will not be identified 
in any publication or presentation on the results of the research. 
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 What If I Change My Mind Later? 
You can withdraw from the study at any time without reason or justification – you just need to tell 
your doctor. We will then discard the blood sample that you have provided.  
What Are The Benefits? 
There are no direct benefits to you from taking part in this research. However, information gained 
from this research may benefit other people in the future.  
What Are The Risks? 
The risks of taking a blood sample are rare and include discomfort, bruising and infection. If you 
suffer any such side effects, please let us know.  
How Will My Samples Be Stored? 
Your blood sample will be stored in a locked freezer in a secure room and identified by a code that 
cannot be traced back to you personally. Only authorized people are allowed to enter. 
Will I Be Paid for Taking Part? 
No. You will not be paid for taking part in this study. 
Will I Be Paid For The Use Of My Results? 
No. You will not be paid for the use of your results. 
 
Contacts for Questions 
Dr Michael Mahmoudi (Principle Investigator): 01483 684640 
Professor Christopher Fry (Scientific Lead): 01483 688510 
Dr Martha Wrigley (Clinical Trials Manager): 01932 723534 
 
Your help and cooperation is greatly appreciated. 
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Appendix C – Patient Consent Form for Recruited Patients  
 
Centre Number:        Study Number:   
 
Patient Identification Number for this trial:  
 
Protocol version and consent version number: 5/3 
 
REC Ref No: 13/LO/0238  
 
Patient Consent Form – copy in notes, database and to the patient 
 
Title of Project: DECODE- DNA DamagE and Repair in Atherosclerotic COronary 
Artery DiseasE 
 
Investigator: Dr Michael Mahmoudi 
Name of Researcher: Dr. Nikunj Shah 
 
The patient should complete this form herself/himself.                                               Please Initial box 
I confirm that I have read the Participant Information Sheet dated 20th May 2015 (Version 5) for the 
above study. I have had the time to consider the information, ask questions and have had these 
answered fully.                  
                                                                                                                                   
I understand that participation is entirely voluntary and that I may withdraw from the study at any 
time without giving reason, without my medical care or legal rights being affected.         
 
I understand that all data will be anonymous. Data may be submitted for publication and presented at 
scientific meetings.                  
                                                                                                                                    
I understand that the research team may require access to relevant sections of my medical notes. I give 
my permission for this to occur.                
                                                                                                                                    
I consent to my General Practitioner being informed of my participation.      
 
I consent to participating in the study “DNA Damage and Repair in Atherosclerotic Coronary Artery 
Disease”.                            
                                                                                                                                    
I understand that I may be attending the Hospital for a blood test after 30 days of my participation in 
the study and potentially a general check-up 1 year after participation in the study.      
                                                                                                                                    
I understand that I may be included in the study despite having no coronary disease  
as a control .               
 
 
_________________________ 
 
_______________________ 
 
__________________ 
Name of Patient Date Signature 
 
_________________________ 
 
_______________________ 
 
__________________ 
Name of person taking consent Date Signature 
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Appendix D – Ethical Approval for The DECODE Study 
 
  
NRES Committee South East Coast - Surrey  
Bristol Research Ethics Committee Centre  
Whitefriars  
Level 3, Block B  
Lewins Mead  
Bristol  
BS1 2NT  
  
Tel: 01173421330   
  
22 June 2015  
  
  
Dr Nikunj Shah   
Cardiology Research Fellow   
Faculty of Health and Medical Sciences   
University of Surrey   
Duke of Kent Building   
Guildford   
GU2 7TE  
  
Dear Dr Shah,  
  
Study title:  DNA Damage & Repair Proteins In Patients with  
Atherosclerotic Coronary Artery Disease (DECODE Study)  
REC reference:  13/LO/0238  
Amendment number:  Substantial Amendment 1  
Amendment date:  20 May 2015  
IRAS project ID:  120221  
  
The above amendment was reviewed by the Sub-Committee in correspondence.   
  
Ethical opinion  
  
The members of the Committee taking part in the review gave a favourable ethical opinion of 
the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
The Sub-Committee asked for further clarification in relation to who the updated Participant 
Information Sheet (PIS) and Consent form are meant for.   
130 
 
You stated that the PIS and consent form are relevant to all groups (control and patient 
groups). You noted that the amendment takes into consideration that the patients listed 
for the procedure (angiogram) may not have atherosclerotic disease and may 
consequently be included in the control arm. Therefore, you confirmed that the 
documents are for all patients recruited (NSTEMI, stable angina and controls) noting 
that even if the patient does not have the disease, blood may be taken for the purposes 
of involvement as a control.   
  
  
The Sub-Committee accepted your response and subsequently approved the following 
changes:  
  
1. Updated Participant Information Sheet and Consent form  
2. Updated Protocol  
  
  
Approved documents  
  
The documents reviewed and approved at the meeting were:  
  
Document    Version    Date    
Notice of Substantial Amendment (non-CTIMP) [Amendment document 
DECODE]   
Substantial  
Amendment  
1   
20 May 2015   
Participant consent form [Patient consent form version 3 [Final]]   3   20 May 2015   
Participant consent form [Patient consent form version 3 [Tracked]]   3   20 May 2015   
Participant information sheet (PIS) [DECODE PIS version 5 [Final]]   5   20 May 2015   
Participant information sheet (PIS) [DECODE PIS version 5 [Tracked]]   5   20 May 2015   
Research protocol or project proposal [(Clean Copy)]   4   20 May 2015   
Research protocol or project proposal [(Tracked Copy)]   4   20 May 2015   
  
Membership of the Committee  
  
The members of the Committee who took part in the review are listed on the attached sheet.  
  
R&D approval  
  
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D approval 
of the research.  
 Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK.  
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We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/   
  
13/LO/0238:    Please quote this number on all correspondence  
  
Yours sincerely  
  
Dr Mark Atkins Chair  
  
E-mail: nrescommittee.secoast-surrey@nhs.net   
  
  
Enclosures:  
  
List of names and professions of members who took part in the 
review  
Copy to:  Dr Isaac John, Ashford & St Peter's Hospital NHS Trust  Dr 
Michael Mahmoudi, University of Surrey  
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